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ABSTRACT
SYSTEMS BIOLOGY OF GENE REGULATION ACROSS SCALES:
FROM SINGLE MOLECULES TO CELLULAR IDENTITIES
Ian A. Mellis
Arjun Raj, Ph.D.
Gene regulation takes many forms and is responsible for phenotypes at the scale of individual
molecules up through the scale of complex tissue functions. At the smallest level, single-base
modifications of individual mRNA molecules transcribed from the same gene can lead to
functionally different protein products. In the first chapter of this thesis, I develop a new method,
inoFISH, and associated analytical tools to visualize and quantify RNA editing with single
molecule resolution in single mammalian cells. Using this new method in conjunction with
mathematical modeling I show that the heterogeneity of single-cell mRNA editing rates across a
population depends on the gene of interest. Further, I characterize subcellular localization
patterns of edited and unedited mRNAs. At the other end of the spectrum, the regulation of
transcriptome-wide patterns of gene expression can underpin cellular identities. In the second
chapter of this thesis I develop a new experimental design and analytical framework for
prioritizing lists of transcription factors that can be used for directed changes of cellular identity.
With Perturbation Panel Profiling (P3), I show that cardiomyocyte lineage-driving transcription
factors are more frequently up-regulated, or “perturbable”, than other highly expressed
transcription factor genes. I subsequently demonstrate that a known cocktail of cardiomyocyteperturbable transcription factors enables cardiac transdifferentiation of several types of human
fibroblasts. Lastly I extend perturbability-based selection of transcription factors to another
biological context, i.e., fibroblast reprogramming to pluripotency. I show that fibroblast-perturbable
factor knockdown often enables more efficient fibroblast reprogramming. Together, my thesis
makes critical steps toward understanding and engineering gene regulation through the
development of a diverse array of methods, experimental designs, and analytical frameworks.
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INTRODUCTION

In its myriad forms gene regulation generates diversity in the function of the genome at many
scales of biological organization: from single-molecule-scale copies of transcripts in single cells to
transcriptome-scale patterns of gene expression across tissues. Scientific questions about gene
regulation at these different scales come with different accompanying challenges. In this thesis I
identify and resolve some of these diverse challenges for two different questions about the
function of gene regulation at two different levels of biological organization.

At the level of single molecules in single cells, RNA editing is a form of gene regulation that
generates diversity in the base composition of transcripts arising from the same gene. These tiny,
yet precise, differences are sometimes associated with life-or-death outcomes for single cells but
are extremely challenging to study due to a lack of sufficiently sensitive experimental techniques.
In the first chapter of this thesis I develop a new experimental technique and improve associated
analytical tools to enable unprecedented single-molecule resolution of RNA editing in single cells
in situ. I apply this technique to the study of several genes in neural lineage cell lines. These
genes include GRIA2, which, when its RNA editing is disturbed, is implicated in the loss of
neurons in models of neurodegenerative diseases.

At the level of the entire transcriptome across tissues, transcription factor-driven gene expression
patterns can dictate cellular identity. A major goal in the field of cellular engineering is efficiently
directing cells toward a cell identity of interest on demand, e.g., toward pluripotency in the case of
fibroblast reprogramming to induced pluripotent stem cells. However, an outstanding question in
the field is whether we can establish a general procedure for identifying those transcription factors
capable of driving cells toward a cell identity of choice on demand. In the second chapter of this
thesis, I develop a new experimental pipeline and analytical framework for the identification of
1

transcription factors that enhance directed changes of cellular identity when overexpressed or
suppressed.

ONE BASE CAN CHANGE EVERYTHING: RNA EDITING IS IMPORTANT BUT
HARD TO STUDY

Of the more than one hundred known types of RNA editing resulting in chemical base
modification, one of the most common events is adenosine deamination, which results in a base
identity switch from adenosine to inosine (A-to-I).(Piskol et al., 2013; Sakurai et al., 2014) A-to-I
editing, among other effects, changes the complementarity profile of the affected base from
adenosine’s affinity for thymidine to inosine’s affinity for cytosine; inosine functions as a
guanosine analog (Fig. 1a). Researchers have studied RNA editing, including A-to-I editing, in the
context of structural stabilization and regulation of abundant non-coding RNAs (ncRNAs; e.g.,
tRNAs) for decades. However, in addition to affecting the secondary structure of an A-to-I edited
RNA molecule, an inosine resulting from editing could also modulate codon identity, alternative
splicing, or other post-transcriptional regulation of an mRNA.(Flomen et al., 2004; Sommer et al.,
1991)

ADAR enzymes, which catalyze A-to-I editing, are important for normal mammalian physiology:
ADAR mutants have well-characterized phenotypes.(Higuchi et al., 2000; Rice et al., 2012)
Phenotypes resulting from loss of A-to-I editing are not solely due to defects in abundant
ncRNAs. One of the best known examples of conserved ADAR-mediated A-to-I editing of a
mammalian mRNA is that of GRIA2, whose editing results in a non-synonymous Q607R change
in GluR2 subunit of the glutamate receptor, thereby modulating the receptor’s Ca++
permeability.(Sommer et al., 1991) Electrophysiological studies show excessive divalent cation
2

permeability of neurons in model organisms with perturbed editing of GRIA2. Phenotypically,
GRIA2 editing-deficient model rat forebrain neurons are more susceptible to ischemic
insult.(Peng et al., 2006) In humans with ALS, some disease-affected motor neurons appear to
die as a result of glutamate excitotoxicity and have perturbed GRIA2 A-to-I editing
rates.(Hideyama et al., 2012) Research on mouse models has provided evidence suggestive of a
causal role of deficient GRIA2 editing in ALS-like pathology: ADAR knockout mice demonstrate
an

ALS-like

phenotype,

which

is

rescued

upon

exogenous

expression

of

edited

GRIA2.(Hideyama et al., 2010) In addition to GRIA2, serotonin receptor 2C (5-HT2C) is a wellknown A-to-I editing target, with clear effects on receptor activity resulting from A-to-I
editing.(Flomen et al., 2004)

Since the 1990s, the research community has used RT-PCR-based techniques to study editing
rates in these canonical example transcripts.(Sommer et al., 1991) However, little is known about
how editing affects the localization of these mRNAs to specific compartments of the cell, which is
important for understanding the factors that regulate their translation. For example, specific edited
RNAs, such as CTN-RNA, appear to be sequestered in paraspeckles until the cell is exposed to
stress.(Prasanth et al., 2005) Overall, multiple experiments have provided conflicting evidence
about the subcellular localization of edited transcripts, including about GRIA2 with respect to
nuclear retention, affecting how these genes could be post-transcriptionally regulated in stressful
environments.(Jepson et al., 2011; Kumar and Carmichael, 1997; Prasanth et al., 2005; Savva et
al., 2012; Wong et al., 2003)

Additionally, recent transcriptome-wide surveys of A-to-I editing in mammals suggest that there
may be many more mRNA targets than were previously known.(Bahn et al., 2012; Porath et al.,
2014; Ramaswami et al., 2012, 2013; Sakurai et al., 2010, 2014) These studies have put forward
more than 20,000 candidate ADAR targets, most but not all in Alu repeat regions. Several
hundred non-Alu candidate editing sites are conserved between orthologous loci in humans,
3

mice, chimpanzees, and rhesus macaques, suggesting that they may in fact be functional in
mammals.(Ramaswami and Li, 2014) However, as above, little about the basic biology of ADARmediated mRNA A-to-I editing is conclusively known.

In combination, these results provide strong motivation for developing a new generation of
precise techniques for studying RNA editing, and for using these tools to begin the quantification
of mRNA editing rate perturbation in diseases such as ALS.

In chapter 1 of this thesis I apply a variant of the single-molecule FISH (smFISH) method to
characterizing the subcellular localization of A-to-I edited transcripts and to identifying the
distribution in editing rates in populations of neural lineage cells. (Levesque et al., 2013; Mellis et
al., 2017; Raj et al., 2008)

THE WHOLE TRANSCRIPTOME MATTERS: THE STATE OF IDENTIFYING
LINEAGE-DRIVING TRANSCRIPTION FACTORS

Cellular transdifferentiation, i.e., transforming a cell of one type into another type, is a longstanding goal in the biomedical field. However, the biology of many terminally differentiated cell
types (e.g., fibroblasts and cardiac myocytes) is such that they are phenotypically stable in the
sense that they retain their cell type even when subjected to perturbation. A striking but
commonplace example of this stability is growing cells on tissue culture dishes, in which cells are
clearly not in their native context, but still retain recognizable features of being, say, a fibroblast or
cardiac myocyte.

4

Decades of work have shown that one can, however, directly change cellular identity through
manipulation of genetic material. In the 1950s, Briggs and King and Gurdon et al. demonstrated
that frog blastula whole-nuclear transplantation could transform eggs into cells resembling
zygotes, capable of complete development to sexually mature individuals.(Briggs and King, 1952;
Gurdon et al., 1958) Relatedly, in the 2000s, Sul et al. showed that transplantation of the whole
transcriptome of a rat astrocyte into a rat neuron was sufficient to transform the neuron into an
astrocyte-like cell.(Sul et al., 2009)

The work of Davis et al. showed that one can, further, transform one cell type into another
through ectopically inducing expression of a small set of genetic factors (Davis et al., 1987)
known to regulate larger gene expression programs. The celebrated work of Yamanaka
(Takahashi and Yamanaka, 2006) showed that one can similarly turn a terminally differentiated
cell into a pluripotent stem cell. These genetic factors are often transcription factors, which
appear to induce reprogramming through the regulation of large genetic programs akin to those in
the target cell type. However, a major issue in the field is knowing which factors to test for their
potential for reprogramming to a fate of interest. Given that many of them work best in a “cocktail”
consisting of multiple factors, brute force genome-wide screening is not feasible, leaving us with
the requirement to narrow the list of potential factors down before testing them experimentally.

Thus far in the field, there have been two broad sets of approaches to identifying putative
reprogramming factors. The approach taken by Yamanaka and many subsequent studies has
been to take a limited pool of factors known to be involved in the maintenance of pluripotent stem
cells, and then to methodically test combinations of subsets of those factors to see which ones
were most critical to inducing cells to reprogram. Such an approach is no doubt powerful and
rooted in years of painstaking developmental biology, but a fundamental problem is that it is
limited in scope to factors that have a known role in development. In principle, however, many
forms of transdifferentiation have no real analogy in developmental biology, and as such, it is
5

possible that there are many other factors that could potentially induce transdifferentiation that
are completely independent of those involved in the developmental trajectory. Identification of
such unknown factors could have a huge impact on our ability to transdifferentiate cells.

Recent studies have tried to use molecular profiling of cells to reveal these factors (e.g., CellNet
(Cahan et al., 2014; Morris et al., 2014; Radley et al., 2017), Mogrify (Rackham et al., 2016), and
others (D’Alessio et al., 2015; Tomaru et al., 2014)). These studies use primarily transcriptome
data (microarray, CAGE, or RNA sequencing) to identify transcription factors with predicted gene
regulatory activity that is highly specific to a particular cell type. The underlying hypothesis in
these studies is that these lineage-specific factors might also be lineage-driving in the sense that
their expression can induce cells to transform into the type for which they are most specific.
However, in practice, this strategy has met with fairly limited success. For instance, CellNet used
thousands of profiles to try to identify factors for a B-cell to macrophage transdifferentiation
protocol, but it didn’t identify the most important known factor in the transformation: C/EBPα
overexpression. Mogrify also was a limited success: it did find some previously known factors, but
failed to identify others. In the years subsequent to publication, to my knowledge, neither has
been used to prospectively identify new transdifferentiation protocols.

A central conceptual limitation of these approaches is that they only identify factors whose
expression or activity is specifically associated with the cell type, irrespective of how that cell type
is able to maintain its overall phenotypic stability. In principle, there may be sets of factors that
are neither cell type-specific nor associated with a cell type’s development that are nonetheless
important for maintaining its cellular identity. How, then, might one identify these additional
factors, whose role in cell identity maintenance suggests that they are promising candidates for
inclusion in a transdifferentiation protocol?

6

In the second chapter of this thesis, I develop an experimental and analytical pipeline for
identifying transcription factors for use in directed changes of cell identity through their
association with cellular responses to a variety of perturbations. I subsequently test several
candidate factors identified in studies of perturbed cardiac myocytes and dermal fibroblasts in
cardiac transdifferentiation and iPSC reprogramming experiments.

7

CHAPTER 1: VISUALIZING ADENOSINE-TO-INOSINE RNA
EDITING IN SINGLE MAMMALIAN CELLS
Conversion of adenosine to inosine is a frequent type of RNA editing, but important details about
its biology remain unknown due to a lack of imaging tools. We developed inoFISH to directly
visualize and quantify adenosine-to-inosine edited transcripts in situ. We found that editing of
GRIA2, EIF2AK2, and NUP43 is uncorrelated with nuclear localization and paraspeckle
association. Further, NUP43 exhibits constant editing levels between single cells while GRIA2
levels vary.

ADENOSINE DEAMINATION RNA EDITING CHANGES BASE PAIRING

Many RNA species are modified to contain non-canonical bases, a process known as RNA
editing. The most prevalent type is adenosine-to-inosine editing(Bass and Weintraub, 1987),
wherein adenosine deaminases (e.g., ADARs) enzymatically modify an adenosine base to an
inosine base (Figure 1.1), disruption of which leads to defects in hematopoiesis (Liddicoat et al.,
2015) and neurological function(Higuchi et al., 2000). It has been speculated that adenosine-toinosine RNA editing influences subcellular localization patterns like nuclear retention(Chen and
Carmichael, 2009; Kumar and Carmichael, 1997; Prasanth et al., 2005; Zhang and Carmichael,
2001), but the lack of visualization tools has left this and other hypotheses untested. We thus
developed inosineFISH (inoFISH), a fluorescence in situ hybridization-based method for directly
imaging adenosine-to-inosine RNA editing events with single-molecule resolution.

8

Figure 1.1

9

COMPETITIVE HYBRIDIZATION AS A STRATEGY FOR DETECTING RNA
EDITING IN SITU

Discriminating edited from unedited RNA via RNA fluorescence in situ hybridization (RNA FISH)
is difficult because it relies on the hybridization of oligonucleotide probes to visualize the target of
interest(Raj et al., 2008). Short oligonucleotides bind nonspecifically while long oligonucleotides
cannot discriminate single-base differences. We thus used a ‘toehold probe’ strategy(Levesque et
al., 2013) to reduce the initial hybridization region of our detection probes in order to confer
selectivity based on single-nucleotide differences (Figure 1.2). Our scheme took advantage of
the fact that inosine preferentially binds to cytosine rather than thymine by using two detection
probes that compete to target the unedited, adenosine-bearing sequence using a thymine, and
the edited, inosine-bearing sequence using a cytosine. Upon specific binding, the “mask”
sequence is released by strand displacement to stabilize hybridization. However, single
oligonucleotides are still prone to nonspecific binding, so we simultaneously used smFISH (the
“mRNA guide” probe) to target a constant region of mRNA, coupled to a unique fluorophore
(Figure 1.2). The mRNA guide showed us where to look for specific detection probes.

10

Figure 1.2: Overview of the inoFISH probe design strategy
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VALIDATING INOFISH OF GRIA2 IN HUMAN NEURAL LINEAGE CELL LINES

To test whether inoFISH could visualize adenosine-to-inosine editing, we chose the canonical,
well-studied example of the Glutamate receptor 2 transcript (GRIA2). (GRIA2 editing is critical for
neuronal function(Seeburg et al., 2001) and defects in GRIA2 editing have been associated with
ALS(Yamashita et al., 2012).) We confirmed that GRIA2 was edited by comparing genomic DNA
and cDNA sequence in SH-SY5Y cells (Figure 1.3), and verified that it is a viable target for
smFISH based on probe design constraints.(Raj et al., 2008) Combining four biological replicates,
10.53% of mRNA guides uniquely colocalized with adenosine or inosine detection probes, with
5.25% and 5.28% of GRIA2 guides colocalizing with the adenosine-detection and inosinedetection probes respectively Figure 1.4a,b). The estimated mean editing level for GRIA2 was
57.3% (95% confidence interval: 45.1%, 69.5%, full statistical model in Appendix A).

To confirm that detection probes did not colocalize with guide probes by random chance, we
measured the rate of random colocalization by computationally shifting guide spots by 5 pixels in
both the X and Y direction (“Pixel-shift”), thereby moving them outside the range of any true
colocalization events (see Appendix B; Figures 1.4b, 1.5). Pixel-shift analysis reduced
colocalization to 1.83% and 1.16% for adenosine and inosine, respectively, showing that most of
colocalization events were specific. (Substituting an unrelated guide probe yielded similar results;
Figure 1.6.) To check for dye-specific effects, we swapped fluorophores on the detection probes
(Figures 1.4b, 1.5), revealing variation in the estimated mean editing level of 22% (Figure 1.5,
and Appendix A). Together, these findings show that inoFISH can measure editing levels
provided that one checks for dye-specific biases in detection probe sets.
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Figure 1.3: Sanger sequencing of GRIA2 RT-PCR product

GRIA2 edit site (“Q607R”)
chr4: 158257875 (+)

GRIA2

C T T T A T GCA GC A AGGA T GCG
genomic DNA

CT T T A TGC

I
GC A AGGA T GCG
A

cDNA

Figure 1.3: Sanger sequencing of GRIA2 RT-PCR product
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Figure 1.4
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Figure 1.4: inoFISH discriminates between inosine and adenosine.
(a) Fluorescence micrographs of Cal Fluor 610–labeled guide
probe detecting GRIA2 mRNA (upper left), Cy5-labeled inosine
detection probe (upper right) and Cy3-labeled adenosine detection
probe (lower left), colocalized (lower-right). Scale bar, 5 μm. (d)
GRIA2 inoFISH results in SH-SY5Y cells (4 biological replicates),
including pixel-shift and dye-swap controls; inoFISH probe detection efficiencies per-replicate (points) and mean +/- s.e.m.. Full
summary of guide spot labels (pies; mean over all replicates).
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Figure 1.5

Figure 1.5: Expanded controls for GRIA2. InoFISH results for
each replicate, including pixel-shift and dye-swap controls for
GRIA2 in SH-SY5Y cells.
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Figure 1.6

Figure 1.6: False-colocalization of GRIA2 detection probes with SFPQ
guide probes. (top) Schematic representation of the experiment. Control
experiment is normal GRIA2 inoFISH with GRIA2 detection probes. On the
right, the guide probe has been replaced to target SFPQ with the GRIA2
detection probes. (bottom) Fraction of colocalized guides with GRIA2 (left)
and SFPQ (right).
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To verify that inoFISH signals were specific to inosine bases and not adenosine or guanosine
bases, we altered the frequency of inosines in two different ways. GRIA2 mRNA is primarily
edited by the enzyme ADAR2, so we used siRNA to knock down ADAR2 mRNA levels by 60% in
SH-SY5Y cells(Melcher et al., 1996; O’Connell et al., 1997). We observed a concomitant
reduction in mean estimated GRIA2 editing level from 65% to 14% (Parametric bootstrap p =
0.0004, see Appendix A; Figure 1.7a,c). We also chemically modified inosine bases with
acrylonitrile on the N1 position to prevent base pairing to cytosine(Sakurai et al., 2010; Yoshida
and Ukita, 1968), reducing observed editing level from 52.1% to 13.5% (Parametric bootstrap p =
0.0006) (Figure 1.7b,d).

Additionally, we designed a guanosine-carrying “false detection” probe, which should not bind to
either the edited or unedited transcript; it did not bind more than expected by chance (Figure
1.8). These results show that inoFISH specifically discriminates adenosine and inosine bases.

COMPARING EDITING RATE ESTIMATES OF INOFISH AND OTHER METHODS

We validated inoFISH estimates of editing levels by comparing them to three established
population-based methods (Figure 1.9). We generated GRIA2 cDNA and estimated editing ratio
either through Sanger sequencing or by digesting with a restriction enzyme specific to cDNA from
the edited transcript(Paschen et al., 1994). We also cloned and sequenced individual GRIA2
cDNA molecules. We found editing ratios of 59%, 54.9% and 50%, respectively, consistent with
the 57.3% mean estimated editing level (95% confidence interval: [45.1%, 69.5%]) measured by
inoFISH. Publicly available RNA-sequencing data from untreated SH-SY5Y cells also revealed
GRIA2 editing (see Appendix B and Figure 1.9).
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Figure 1.7
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Figure 1.8
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Figure 1.9: GRIA2 editing levels estimated by inoFISH and traditional methods
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IDENTIFICATION OF CANDIDATE INOFISH-COMPATIBLE RNA EDITING
SITES WITH

RNA-SEQ

Besides the well-studied editing target GRIA2, we wanted to test inoFISH on editing targets that
are less commonly studied in the literature. For these we referred to the literature, to the RADAR
database of RNA editing, and to publicly available RNA-seq data for screening. We identified
NUP43 and EIF2AK2 as targets 1) with conserved editing sites across humans, chimps, and
mice; 2) that are studied by a small number of research groups; 3) that are candidate editing
targets in published transcriptome-wide adenosine-to-inosine editing screens; and 4) that have
editing sites amenable to inoFISH probe designs. (Figure 1.10)

Then we wanted to check if these transcripts were also edited to any extent in the neural lineage
cell lines we were studying: SH-SY5Y and U-87 MG. Therefore we downloaded publicly available
RNA-seq data for these cell lines and conducted our own assessment of A-to-I editing at the
annotated editing sites. We identified three sites amenable to inoFISH probe design across these
two genes, 1 in NUP43 and 2 in EIF2AK2. We validated as editing targets by Sanger sequencing
of genomic DNA and cDNA (Figure 1.11). For two of these sites we were able to design inoFISH
detection probe sets that gave colocalization with guide probes above pixel-shift estimates of
random chance.

21

Figure 1.10

LSG1
chr3: 194373832 (-)

candidate targets
from RADAR or literature
check for conservation

avoid repeat-rich regions

RNA-seq screen
in cells of choice

MYO1C
chr17: 1373518 (-)

check expected cell population-wide
editing rate by RT-PCR + Sanger seq
inoFISH failure point:
avoid frequent nearby (± 20bp) edits
control for de novo C --> T mutation
in cells of choice by genotyping
inoFISH
Figure 1.10: Outline of experimental design pipeline for inoFISH, including representative
results (LSG1 RT-PCR/Sanger and MYO1C genotyping/Sanger) at critical steps in the target
selection process.
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Figure 1.11
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Figure 1.11: Sanger sequencing of EIF2AK2 and
NUP43 RT-PCR products
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SUBCELLULAR LOCALIZATION OF EDITED AND UNEDITED TRANSCRIPTS IN
NEURAL LINEAGE CELL LINES

We next measured the subcellular localization of edited and unedited transcripts. Previous
studies used cell fractionation to show that unmodified RNAs exist in both the nucleus and the
cytoplasm, whereas hyper-edited RNAs—but not selectively edited RNAs—were predominantly
nuclear(Kumar and Carmichael, 1997),(Zhang and Carmichael, 2001). Other studies have shown
that mRNAs containing Alu repeats, which are prone to adenosine-to-inosine editing, are
inefficiently exported to the cytoplasm(Chen and Carmichael, 2009).

We therefore looked for associations between editing status and subcellular localization of GRIA2
transcripts. We classified GRIA2 transcripts as nuclear if they overlapped with the nuclear stain
DAPI. Estimated GRIA2 editing levels were roughly equal in both cellular compartments (p =
0.38; Figure 1.12a, 1.13a). (Uncharacteristically of most mRNAs, 93.4% of GRIA2 transcripts
localized to the nucleus, though they were still translated; Figure 1.14)

We also used inoFISH to visualize localization of adenosine-to-inosine editing in two additional
targets: the hyper-edited transcript EIF2AK2(Wang et al., 2013) (Figure 1.12b) as well as the
Alu-bearing NUP43 (Chen and Carmichael, 2009) (Figure 1.12c) in U-87 MG cells (Figure 1.10),
which We found that 6.91% and 5.57% of EIF2AK2 guide spots colocalized with adenosine- and
inosine-specific detection spots, respectively (Figures 1.12b, 1.15), giving a population-wide
mean editing level estimate of 36.4% (95% confidence interval: [20.4%, 53.1%]). For NUP43,
11.3% and 12.4% of guide spots colocalized with the adenosine- and inosine-specific detection
spots (Figures 1.12c, 1.15), giving a population-wide editing level estimate of 53.2% (95%
confidence interval: [45.1%, 61.2%]). In both cases, the editing level did not vary between
nucleus and cytoplasm (p=0.18, 0.81 for EIF2AK2, NUP43, respectively); (Figures 1.12b,c,
24

1.13). Note that the three inoFISH targets studied had detection efficiencies of 10%, 12% and
24%; the reasons for this variability is unknown, but it is within previous bounds(Levesque et al.,
2013; Shaffer et al., 2015). As before, cyanoethylation reduced the percentage of inosinedetection probe colocalization with guide probe for both EIF2AK2 and NUP43, again showing
specificity (Figure 1.16).
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Figure 1.12
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Figure 1.12: Analysis of subcellular localization using
inoFISH. Nuclear localization analysis reveals no significant differences (parametric bootstrapping) in editing
levels for each target between nucleus and cytoplasm.
(a) GRIA2 (n = 4 biological replicates; p = 0.38), (b)
EIF2AK2 (n = 3; p = 0.18) and (c) NUP43 (n = 2; p =
0.81) transcripts: representative overlays and fractions of
labeled transcripts found to be unedited or edited (inlay).
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Figure 1.13

Figure 1.13: Mean editing level estimate distributions for all three targets. Boxplots of 10000
parametric bootstrapped samples of editing level per boxplot for GRIA2 (top), EIF2AK2 (middle), and NUP43 (bottom). Mean editing level models resampled irrespective of subcellular
localization (left) and considering nuclear vs cytoplasmic localization (right).

27

Figure 1.14
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Figure 1.15

Figure 1.15: Expanded controls for EIF2AK2 and NUP43 inoFISH.
InoFISH results for each replicate, including pixel-shift and dye-swap
controls for EIF2AK2 in U-87 MG cells (top) and NUP43 in U-87 MG
cells (bottom).
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Figure 1.16:
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Figure 1.16: Cyanoethylation reduces number of detected inosines in situ.
inoFISH mean +/- s.e.m after cyanoethylation treatment from a minimum of 2
biological replicates (left) including pixel-shift and dye-swap controls per replicate (right) for GRIA2 in SH-SY5Y cells (top), EIF2AK2 in U87 MG cells (middle), and NUP43 in U87 MG cells (bottom).
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ASSOCIATION OF EDITED AND UNEDITED GRIA2 TRANSCRIPTS WITH
NUCLEAR PARASPECKLES

InoFISH also allowed us to test whether edited transcripts are trafficked to nuclear
paraspeckles(Prasanth et al., 2005). We performed inoFISH together with single-molecule RNA
FISH of NEAT1 RNA, a marker of nuclear paraspeckles(Sunwoo et al., 2009), in SH-SY5Y cells
(Figure 1.17), revealing that 8.57% of all GRIA2 transcripts colocalized with paraspeckles
(Figure 1.17). Simulations (see Appendix B) showed that the observed rate of GRIA2paraspeckle association was 1.7-fold greater than expected by random chance (Simulation of
GRIA2-paraspeckle association rate null distribution for one representative replicate p < 0.001,
see Online Methods).

We then used inoFISH to determine whether edited or unedited GRIA2 transcripts were
preferentially associated with paraspeckles. We found no significant differences in the editing
status in paraspeckles for GRIA2 in SH-SY5Y cells (p = 0.44, determined via simulation, for one
representative replicate; Figure 1.17), demonstrating that edited GRIA2 transcripts in SH-SY5Y
cells do not necessarily preferentially associate with paraspeckles.
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Figure 1.17
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VISUALIZATION OF UNEDITED NUP43 TRANSCRIPTS AT THE SITE OF
TRANSCRIPTION

We next used inoFISH to determine whether adenosine-to-inosine editing is co-transcriptional or
post-transcriptional. Introns mark transcription sites, and colocalization of edited transcripts with
intron signal would suggest that editing can occur co-transcriptionally. We concurrently performed
NUP43 inoFISH with single-molecule FISH targeting NUP43 introns in 212 U-87 MG cells (Figure
1.18), observing 17 total transcription sites, of which 5 transcription sites contained unedited
NUP43 and none containing edited NUP43 (Figure 1.18). This result does not rule out cotranscriptional editing of NUP43 altogether, but does suggest that some NUP43 editing may be
post-transcriptional.

GRIA2 AND NUP43 RNA EDITING LEVELS ACROSS A POPULATION

We also looked for evidence of fluctuations in editing level from cell to cell. We simulated
inoFISH results in the cases of uniform (Figure 1.19a) or variable editing levels in single cells
(Figure 1.19b). We found that GRIA2 editing in single cells was not consistent with the constant
editing level model, suggesting per-cell heterogeneity in GRIA2 editing levels (Figure 1.19c).
NUP43 editing in U-87 MG cells, however, was consistent with the constant-editing level model
(Figure 1.19d). Thus single-cell fluctuations in the level of editing may occur in a target-specific
manner.
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InoFISH provides a direct method for visualizing adenosine-to-inosine RNA editing in single cells
with single-nucleotide resolution. Cell population-wide studies lack the resolution to provide
information such as subcellular localization and cell-to-cell variability of RNA editing. This new
tool will enable researchers to answer basic questions about edited RNA species and will enable
a deeper understanding of the biology of adenosine-to-inosine editing.
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Figure 1.18
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Figure 1.19
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Figure 1.19: Single-cell analysis of inoFISH.
Simulated inoFISH results assuming (a)
binomially-distributed per-cell counts of
edited and unedited transcripts; or (b) two
populations of cells, one population with
95% editing and the other with 5% editing,
mixed in proportion according to the population-wide editing level (c) Single-cell
analysis of GRIA2 inoFISH results pooled
over all 4 replicates and simulation of the
exact conditional null distribution of -log(likelihood) of the data under the binomial
model specified in (a)(inset) (d) Single-cell
analysis of NUP43 inoFISH results pooled
over all 4 replicates (left) and simulation of
the exact conditional null distribution of
-log(likelihood) of the data under the binomial model specified in (a) (inset, see
Appendix A).
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CHAPTER 2: PERTURBATION PANEL PROFILING (P3)
IDENTIFIES TRANSCRIPTION FACTORS THAT ENHANCE
DIRECTED CHANGES OF CELLULAR IDENTITY

MOST CURRENT PROTOCOLS FOR DIRECTED CHANGES OF CELL IDENTITY
ARE INEFFICIENT

The directed conversion of one terminally differentiated cell type into another cell type without
passing through a pluripotent intermediate stage, a process known as transdifferentiation, has a
variety of scientific and translational implications. Over the last few years there have been many
important discoveries of new transdifferentiation methods, however, transdifferentiation protocols
for cell types of interest are usually very difficult to engineer, even in vitro. In particular, many
existing transdifferentiation protocols change relatively few cells of the starting cell type and only
do so in a way that incompletely reprograms to the target cell type (Becker et al., 2017; Fu and
Srivastava, 2015). Conversion of adult human fibroblasts to cardiac myocytes, for example, has
been studied by several groups for years, but remains inefficient using genetic factors (i.e., gene
overexpression or knockdown) alone (Mohamed et al., 2017; Nam et al., 2013). Relatedly,
despite more than a decade of study, the reprogramming to pluripotency of many terminally
differentiated cell types also stubbornly remains inefficient.(Cacchiarelli et al., 2015; Takahashi
and Yamanaka, 2016)

Overexpression of transcription factors often occupies the core of transdifferentiation protocols,
with the idea being that these factors coordinate larger gene expression programs that are
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specific to the target cell type. Strategies for identifying sets of transcription factor genes to be
overexpressed or repressed for transdifferentiation fall into two major classes: testing
combinations of a limited number of transcription factors known to influence the development of
the target cell type, and screens of individual additional factors (Cao et al., 2016; Fu et al., 2013;
Nam et al., 2013; Takahashi and Yamanaka, 2006; Vierbuchen et al., 2010; Zhou et al., 2017). In
recent years there have been several improvements to these strategies, each of which have
enhanced the efficiency and fidelity of different transdifferentiation protocols. Several groups have
considered predicted TF gene regulatory activity and specificity of TF gene expression in the cell
types of interest to augment the limited sets of TFs to be tested combinatorially (Cahan et al.,
2014; Morris et al., 2014; Rackham et al., 2016; Tomaru et al., 2014). Others have made clever
use of single-cell techniques and CRISPR-based epigenome engineering to improve the
throughput of larger, more unbiased factor screens (Black et al., 2016; Duan et al., 2018; Liu et
al., 2018; Parekh et al., 2018). These new approaches have led to some improvement in the
efficiency and accuracy of transdifferentiation toward several cell types across all three germ
layers, but there is still plenty of room for improvement (Guo and Morris, 2017).

Here we propose a complementary experimental and analytical strategy, Perturbation Panel
Profiling (P3), for the selection of transcription factor genes for transdifferentiation and other
cellular reprogramming protocols. Different cell types display unique and complex phenotypes,
but are unified by one major property: individually, each cell type is often resilient to a variety of
minor perturbations. For example, in vivo myocytes remain myocytes and fibroblasts remain
fibroblasts when challenged with changes in their environments, such as when people get sick,
exercise, or take medications. That is, many mature cell types stabilize their identity in response
to perturbation. In vitro, much the same can be seen when manipulating nonessential
components of primary cell culture conditions. Can we use this common property of different cell
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types—phenotypic stability to perturbation—to prospectively identify transcription factors that are
capable of specifying a cell type of interest?

PARALLEL SMALL-MOLECULE PERTURBATIONS OF FIBROBLASTS AND
CARDIOMYOCYTES

Our first major experimental goal was to observe gene expression patterns transcriptome-wide in
the cell types of interest exposed to a wide variety of perturbations. Specifically, we set out to
conduct RNA-seq on hundreds of parallel bulk samples of each cell type of interest, cultured
under standard (i.e., control) and tens of perturbed conditions. Ultimately we hoped to enhance
directed changes of cell identity of human fibroblasts, either to cardiomyocyte-like states or more
generally to other cell identities, like pluripotent stem cells. For our perturbation panels we used
samples of human fibroblasts (GM942, Coriell) and genetically matched iPSC-derived
cardiomyocytes (iCard-942) (Figure 2.1). We selected small molecule perturbagens in the
SelleckChem Bioactive Library targeting any kinases or G protein-coupled receptors (GPCR) in
order to induce in vitro perturbations that lead to changes in intracellular signal transduction
(Table 2.1). Additionally, in order to simulate as many different types of perturbation as possible
while still using small molecule drugs, we minimized redundant primary target set overlap, using
information about signaling pathways and corresponding targets provided by the manufacturer,
SelleckChem. We settled on a list of 100 drugs, administered individually or in pairs, for a total of
75 different perturbation culture conditions (Figure 2.2).
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Figure 2.1
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Figure 2.2
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Figure 2.2: GM00942 fibroblast and iPSC-derived iCard-942
samples processed for P3
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A POTENCY-BASED DRUG DOSING SCHEME FOR PERTURBATION PANEL
PROFILING

(P3)

We first developed a dosing scheme that enabled screening of a large number of drugs that
would perturb fibroblasts and cardiomyocytes in culture. In this scheme we wanted to avoid
wasted samples that are either unperturbed by too low a drug dose or lethally perturbed by too
high a dose. Therefore, we started by dosing parallel cultures of GM00942 dermal fibroblasts with
a pilot panel of 12 drugs at a fixed concentration (100 nM) for 2 days, each in triplicate, along with
vehicle controls (see Appendix C). We prepared RNA sequencing libraries in parallel for all
samples using RNAtag-seq (Shishkin et al., 2015), and we quantified the number of differentially
expressed genes in each drug condition relative to vehicle controls. We observed that only 7 of
the 12 perturbations induced any differential expression of genes at a concentration of 100 nM
(Figure 2.3).

We next wondered if the extent of gene expression perturbation (i.e., number of differentially
expressed genes induced) was correlated with the potency of the drug. Therefore, we mined the
literature for the annotated IC50s of each drug for each of its known targets. We observed
anticorrelation between the median annotated IC50 of each drug with the number of differentially
expressed genes it induced (Figure 2.4). More potent drugs have lower IC50s, so we concluded
that a strategy for consistently delivering a drug at a high enough dose to elicit a response might
be achieved by tuning the dosage its known IC50s.
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Figure 2.3: Number of differentially expressed genes detected relative to DMSO controls
in GM00942 fibroblasts.
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Following up on this, we set out to identify whether there might be a predictable ratio of a drug’s
known IC50s that we could deliver to elicit a perturbation that was both significant enough to
induce differential gene expression and mild enough to not grossly change the cells. That is, we
also wanted to avoid killing the cells, altering their morphology, or in the case of cardiomyocytes,
inhibiting their stereotypical ability to spontaneously beat in 2D culture. Therefore, we next dosed
parallel cultures of GM00942 dermal fibroblasts with a new panel of 12 drugs, each at 3 drugspecific doses for 2 days (1x, 20x, and 100x the median annotated IC50 of that drug), along with
vehicle controls. We administered the same doses of the same drugs to parallel cultures of iPSCderived cardiomyocytes of the same genetic background (See Appendix C). We again performed
highly parallelized RNA-seq with RNAtag-seq and quantified differential gene expression for each
drug at each dose relative to vehicle controls of the same cell type.

We observed that 9 of 12 drugs induced some differential gene expression in fibroblasts at 100x
IC50 and 10 of 12 drugs induced any differential gene expression in iCards at that same dose,
while generally preserving gross morphology and iCard beating activity (Figure 2.5). At lower
doses, these drugs tended to induce fewer differential gene expression events. Therefore, we
concluded that for a larger set of small molecules with similar classes of targets (i.e., GPCRs and
kinases), we should be able to frequently induce a moderate-strength differential gene expression
response by administering these drugs at 100x the median annotated IC50.
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Figure 2.5: Differentially expressed genes relative to DMSO controls of each cell type at
each annotated drug-specific dose (1x, 20x, and 100x) the median annotated IC50, in nM.
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We next wondered whether there was any information about the drugs that failed to induce any
differential expression that we might use to avoid such lack of perturbation. Therefore we asked
whether gene expression of a drug’s targets in the cell type of interest might be correlated with
the presence or absence of differential gene expression. We found that the targets of the drugs
that failed to induce differential gene expression in fibroblasts were not expressed in fibroblasts
(Figure 2.6). Therefore, we also decided to restrict the list of P3 drugs to those whose targets are
expressed in both GM00942 fibroblasts and iCard-942 cells (See Appendix C).

MOST P3 PERTURBATIONS INDUCE DIFFERENTIAL EXPRESSION PROFILES
WHILE GROSS CELLULAR PHENOTYPES REMAIN STABLE

After 4 days of perturbagen or DMSO-only exposure, we took transmitted light videos of iCard942 cultures to check whether cells were still beating and morphologically similar to controls as a
proxy for maintained cell identity, and found that 63 out of 75 conditions had wells with beating
cells and without evident cell death. Similarly, we took transmitted light images of GM942
fibroblast perturbation cultures and found that 62 out of 75 conditions had wells with fibroblastic
cells and without evident cell death (Figure 2.7). In sum, we developed a strategy for delivering
small molecule perturbagens in a relatively highly parallelized fashion to samples of the same cell
type in a format compatible with bulk RNA sequencing without obviously altering their grossest
phenotypes.
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Figure 2.6
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Figure 2.6: Comparison of number of differentially expressed genes in
GM00942 fibroblasts against the average expression level of drug target
in GM00942 fibroblasts
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Figure 2.7

Figure 2.7: Representative frames from quality control videos for iCards-942 cells in 96-well
format. Note the stretching in cells during contraction, or “beating”, activity.
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We next sought to conduct transcriptome-wide gene expression profiling of the hundreds of
perturbed (and control) samples of cardiomyocytes and fibroblasts. We performed RNAtag-seq in
batches of 96 samples, spreading DMSO controls evenly across each batch.

In our exploratory analysis, we clustered gene expression profiles across the 458 qualitycontrolled samples (454, excluding HeLa outgroup) clustered first by cell type, and then often by
perturbation condition (Figure 2.8). We identified hundreds to thousands of differentially
expressed genes in most perturbed conditions relative to corresponding cell type controls (Figure
2.9, Appendix C). Note that the number of detected differentially expressed genes is powerlimited by relatively low sequencing depth. However, for genes with high expression, i.e., mean
RPM > 20, we estimated that we can detect most differential expression events at the current
sequencing depth (Figure 2.10). (We intentionally chose relatively low sequencing depth as a
trade-off with an increased number of perturbation conditions; this allowed us to focus on
dysregulation patterns of highly expressed genes across a large number of samples.) This shows
that our perturbation panel did in fact elicit perturbation of gene expression levels, even when the
cell’s type, or grossest phenotypes, remained stable.
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Figure 2.8
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Figure 2.8: Heatmap with hierarchical clustering of all quality-controlled
samples based on log2(TPM) values of all genes expressed at 20RPM
in both GM00942 and iCard-942 cells.
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Figure 2.9: Differentially expressed gene counts per drug in GM00942 fibroblasts and
iCard-942.
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Figure 2.10
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Figure 2.10: Downsampling analysis of iCard-942 RNAtag-seq data. Counts per sample
were randomly downsampled to 50%, 70%, and 90% of the total dataset, using two different
random seeds, and re-calculated. Each black line represents the fraction of differentially
expressed genes still detected at the downsampled read fraction. The green line represents
the median fraction of total differentially expressed genes per drug at that downsampled
read fraction. Results are shown for four minimum log2FoldChange filters (0, 0.5, 0.75, and
1). Drugs are only included in this analysis if they have 200 or more differentially expressed
genes detected in the full dataset.
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MOST HIGHLY EXPRESSED GENES ARE DIFFERENTIALLY EXPRESSED
AFTER AT LEAST ONE PERTURBATION

We then wondered whether only a small subset of genes were dysregulated in each cell type
across the 60+ perturbation conditions, or if most genes were dysregulated in response to some
perturbation. To check this, in each cell type for each gene that was highly expressed in controls
of that cell type, we counted the number of perturbations causing differential expression vs.
controls. We found that the vast majority of highly expressed genes in each cell type were
differentially expressed in at least 1 quality-controlled perturbation condition relative to that cell
type’s controls (Figure 2.11), suggesting that most highly expressed genes can be dysregulated
by some of the signaling perturbagens in our library.
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Figure 2.11: Cumulative fraction of genes differentially expressed in at least one
condition as one consider more drugs in the dataset. Only genes with minimum average expression of 10 TPM shown.
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CARDIOMYOCYTE LINEAGE-DRIVING TRANSCRIPTION FACTORS ARE UPREGULATED IN MORE PERTURBATION CONDITIONS THAN OTHER HIGHLY
EXPRESSED TRANSCRIPTION FACTORS

Given that most genes can be differentially expressed in at least one perturbation condition, we
wondered if some genes were dysregulated in more conditions than other genes. In particular, we
wanted to know if known lineage-driving transcription factor genes were dysregulated following a
relatively low or high number of different perturbations, i.e., whether these known lineage-driving
TF genes are more or less “perturbable” than other highly expressed TF genes. If high or low
perturbability is a feature of known lineage-driving TF genes, perhaps it could be used to
prospectively identify other TFs that may also play a role in specifying or maintaining lineage
identity (and therefore might be useful in transdifferentiation experiments). We pre-registered a
set of 14 cardiomyocyte lineage-driving TF genes prior to analyzing our RNAtag-seq data (Figure
2.12). For each of these genes, we counted the number of perturbations that resulted in
differential expression in cardiomyocytes vs. controls. Although we had initially hypothesized that
lineage-driving TFs would be less perturbable than other highly expressed TF genes, we found
the opposite to be true: lineage-driving TFs are highly perturbable.

Specifically, they are up-regulated across many different perturbation conditions (Figure 2.12).
This effect is not explained by differences in the power to detect differential expression due to
differences in average expression levels; i.e., lineage-driving TFs are more perturbable than other
TF genes expressed at the same level in control samples (Figure 2.13A). Further, it is not the
case that lineage-driving TF genes are up-regulated more dramatically on average than other
genes differentially expressed in a similar number of conditions (Figure 2.13B).
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Figure 2.12
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Figure 2.13
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OVEREXPRESSION OF A KNOWN COCKTAIL OF TRANSCRIPTION FACTORS
PERTURBABLE IN CARDIOMYOCYTES ENABLES CARDIAC
TRANSDIFFERENTIATION OF FIBROBLASTS

We then wondered whether we could confirm that known lineage-driving transcription factors,
most of which were highly perturbable, could induce transdifferentiation in the GM00942 dermal
fibroblasts used for P3 profiling. To do this we used pMXs retroviruses to overexpress a cocktail
of 7 transcription factors (7F: GATA4, MEF2C, TBX5, MESP1, ESRRG, MYOCD, and ZFPM2)
previously shown to transdifferentiate other human fibroblasts to a cardiomyocyte-like state.

A major challenge for this project was figuring out how to assess whether cells had entered a
cardiomyocyte-like state after the process of transdifferentiation. I found that many published
methods for such assessments, including cardiac Troponin immunofluorescence (IF), Troponin
promoter-GFP reporters, and Troponin promoter-calcium transient reporters had too high
background (IF) or too low signal (reporters) to be analyzed efficiently in thousands of mostly
negative cells. These methods do work in iCard-942 cells, which are >95% positive. Eventually
we developed a protocol to make post-transdifferentiation samples compatible with smFISH and
its associated high-magnification fluorescence imaging (See Appendix C).

In order to use smFISH to assess transdifferentiation, we designed smFISH probe sets for
markers specific to mature cardiomyocytes, NPPA and TNNT2.(Mohamed et al., 2017) These
probes show high expression of both markers in iCard-942 cells and extremely low expression in
cardiac fibroblasts (Figure 2.14).
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Figure 2.14: TNNT2 and NPPA smFISH counts per cell.
Average of 33 cells per cell type. iCard-942 cells and
immHCF, immortalized human cardiac fibroblasts.
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We cultured 7F- and vehicle control-treated cells under progressively reduced serum conditions
for 24 days following infection and at day 24 observed a small fraction of cells dramatically and
concordantly up-regulate both NPPA and TNNT2 (Figure 2.15). Large-scale scans of
approximately 1000 cells per sample suggested that approximately 1% of cells treated with 7F
either marker gene expression above 25 copies per cell in a single focal plane at 60X
magnification. 0 such cells were observed in vehicle controls (Figure 2.16). Therefore, we can
conclude that some P3-identified frequently up-regulated transcription factors, i.e., members of
7F, were sufficient to induce cardiac transdifferentiation of cells of the genetic background in
which they were identified.

We next tested whether 7F could induce transdifferentiation of fibroblasts from other sources, as
well. Therefore we overexpressed 7F under similar conditions in two additional types of
fibroblasts: an immortalized cardiac fibroblast cell line (immHCF) previously shown by one group
to transdifferentiate with low efficiency upon 7F overexpression and primary cardiac fibroblasts
(GM11169) that have not been studied in this context before. We observed rates of
transdifferentiation in both of these cell lines comparable to the dermal fibroblasts used for P3
analysis. This rate is consistent with published results in immHCF, as well (Figure
2.17).(Mohamed et al., 2017) Therefore, a cocktail of perturbable transcription factors identified in
iCard-GM942 enable transdifferentiation to a cardiomyocyte-like state in fibroblasts of different
genetic backgrounds, as well. This lends further support to the idea that this cocktail is generally
sufficient for inducing cardiac transdifferentiation.
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Figure 2.15

Figure 2.15: smFISH assessment of 7F-mediated transdifferentiation of GM00942 fibroblasts. (top) representative
images of GAPDH, NPPA, and TNNT2 smFISH demonstrating a cell that expresses marker genes NPPA and
TNNT2 at high levels and one cell that does not. (bottom)
smFISH counts per cell of two marker genes for cells after
receiving either vehicle control (MXs-empty) or 7F.
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Figure 2.16
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Figure 2.16: A) Reconstruction and per-gene quantification of smFISH scans of
GM00942 cells exposed to vehicle control (MXs-empty; 2267 cells) or 7F (1693 cells).
One z-slice per cell. Examples of cell with high expression of TNNT2 marked with white
arrowheads. B) Comparison of single-cell TNNT2 and NPPA expression levels for all
cells in smFISH scans.
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Figure 2.17
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Figure 2.17: smFISH assessment of transdifferentiation of immHCF and GM11169 human
cardiac fibroblasts after exposure to vehicle control (MXs-empty) or 7F. Average of 1151 +/- 51
cells per condition.
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Next, we wondered whether any cocktail comprised of highly cardiomyocyte-perturbable
transcription factors would be capable of inducing cardiac transdifferentiation of fibroblasts.
Therefore we selected a set of seven transcription factors from the total list of 47 such factors that
were highly perturbable and highly expressed in iCard-942 cells (7UP: SP3, ZBTB10, ZBTB44,
NFIA, SSH2, ZNF770, and ZFP91. See Appendix C for details on how these factors were
selected). We tested whether overexpression of this set of transcription factors, previously
unstudied in the context of cardiac transdifferentiation, followed by culture in progressively
reduced serum conditions would lead to up-regulation of cardiomyocyte markers. We did not
observe a dramatic increase in TNNT2 and NPPA expression after overexpression of 7UPs in
fibroblasts.

KNOCKDOWN OF TRANSCRIPTION FACTORS THAT ARE PERTURBABLE IN
FIBROBLASTS OFTEN ENHANCES FIBROBLAST REPROGRAMMING TO IPSC

We wondered whether we could use perturbation panel profiling to identify transcription factors
that are presumably important for driving or maintaining another cell lineage, beyond those for
cardiomyocytes. Therefore, we exposed GM00942 fibroblasts in culture to the same perturbation
panel in culture as GM942-iCards and performed RNAtag-seq after several days of perturbation.
We observed similar numbers of detectably differentially expressed genes in fibroblasts as in
iCards across the perturbation panel (Figure 2.9).

Our first question was whether the same genes are differentially expressed in each condition in
both iCards and fibroblasts. We found little overlap in the specific genes that were detectably
differentially expressed in response to the same drug in each cell type (Figure 2.18).
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Figure 2.18: Overlap between differentially expressed genes per drug across
GM00942 fibroblasts and iCard-942.
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Since we found that cardiomyocyte lineage-driving transcription factor genes are frequently upregulated in perturbed cardiomyocytes, we wondered whether transcription factors that are upregulated in fibroblasts across many perturbation conditions could be useful in directed changes
of fibroblasts to a new cell identity. Specifically, our hypothesis was that genes frequently upregulated in fibroblasts may be useful for fibroblast identity maintenance and therefore their
suppression could make fibroblasts more “reprogrammable”. We chose 16 transcription factors
that were frequently up-regulated in fibroblasts and used shRNAs to knock down their expression
levels in hiF-T cells prior to doxycycline-inducible Yamanaka Factor (Oct4, Sox2, Klf4, Myc;
OSKM) over-expression (Figure 2.19). Of these 16 transcription factors, we found that at least 8
reproducibly increased the frequency of fibroblast reprogramming, as measured by counting
Alkaline Phosphatase-positive colonies after 3 weeks of OSKM induction (Figure 2.20). This
success rate, 8/16, is comparable to the validation rate of a recent pooled shRNA screen of
epigenetic regulators of hiF-T reprogramming (Cacchiarelli et al., 2015), 9/23. Overall, this
suggests that transcription factor perturbability is useful for identifying genes useful for directed
changes of fibroblast identity, as well.

In summary, we developed P3 for profiling gene expression differences in cell types of interest
following a broad panel of small molecule perturbations. We found that known cardiomyocyte
lineage-driving genes are frequently up-regulated after perturbation in cardiomyocytes. Further,
we demonstrated that a known cocktail of cardiomyocyte-perturbable transcription factors
enables transdifferentiation of multiple types of human fibroblasts. Additionally, we extended
perturbability to the identification of fibroblast-perturbable factors, the knockdown of which
improves the efficiency of fibroblast reprogramming to pluripotency. Overall, these results suggest
that the high perturbability of lineage-driving transcription factors can be used to prioritize factors
to include in protocols for directed changes of cellular identity.
67

Figure 2.19
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Figure 2.20
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CONCLUSIONS AND FUTURE DIRECTIONS
The components of this thesis represent some of the many different ways in which we can build
tools, design experiments, and construct analytical frameworks for quantitative models of gene
regulatory processes and the effects of these processes on cellular phenotypes. I focused on two
disparate topics of interest to me: RNA editing and cellular identity. While different, these two
topics are both grounded in generating cellular diversity through regulation of a common genome.

In the first chapter I developed a relatively general method for visualizing and quantifying A-to-I
RNA editing of single mRNA molecules with subcellular resolution. Prior to this work, no one had
actually “seen” an edited mRNA before. The state of the art for detecting A-to-I RNA editing
involved RT-PCR-based methods, such as restriction digestion of PCR products or RNA-seq,
which sacrifice resolution in both single-cell quantification and localization.(Higuchi et al., 2000;
Liddicoat et al., 2015) Alternatively, related methods included standard smFISH with
immunofluorescence for enzymes involved in the process of RNA editing, which visualize a
transcript’s physical association with an enzyme rather than its sequence identity (i.e., whether it
is actually edited).(Jepson et al., 2011) Ultimately, in the case of GRIA2, the field required a more
precise tool for studying this sequence-level difference in single cells.

Now we have seen edited mRNAs and their unedited cohorts in single human cells. With
inoFISH, we can measure differences in localization and quantities of edited and unedited
transcripts arising from the same gene within individual cells in situ. Using this new technique, we
observed nuclear and cytoplasmic localization of both edited and unedited transcripts in the same
cells. For the three genes and two cell lines studied, editing levels were not significantly different
between these two cellular compartments. inoFISH also revealed high physical association of
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GRIA2 with nuclear paraspeckles and that this association was possible for both edited and
unedited transcripts. Additionally, we demonstrated that our method could discriminate the editing
status of transcripts at transcription sites, and that we only observed unedited NUP43 transcripts
at their transcription sites (though we of course could not demonstrate a conclusive absence of
edited transcripts at these sites). Lastly, we showed that the distribution of single-cell editing
levels can differ by gene: NUP43 editing levels are homogeneous across a population of cells,
while GRIA2 editing levels are more variable.

In a broader context, inoFISH enables testing of hypotheses about whether single-cell RNA
editing levels are correlated with single-cell-level phenotypes, such as permeability to divalent
cations or cell death. In combination with recent advances in tissue clearing strategies for related
smFISH methods, inoFISH might be used to visualize the editing status of GRIA2 in human
brains with and without ALS lesions.(Symmons et al., 2019)

Furthermore, inoFISH is a proof of principle that smFISH-based methods could be used to
discriminate the editing status of transcripts in single cells in general. For other interesting types
of RNA editing, such as pseudouridylation, we can imagine designing related techniques for
single-molecule resolution of editing status at sites of interest. One could imagine combining
established techniques for selective chemical labeling of pseudouridine bases by CMC
derivatization with a new click chemistry-based technique for amplified smFISH signal to
specifically hybridize clampFISH probes to edited transcripts.(Rouhanifard et al., 2018; Sakurai et
al., 2014)
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In the second chapter of this thesis, I developed an experimental and analytical pipeline for
identifying transcription factors to be used in directed changes of cellular identity based on their
expression levels following a broad panel of perturbations (P3). We used a drug-specific dosing
scheme that allowed us to choose drugs and deliver them at a dose that would reliably perturb,
but not kill, the cells of interest. Our IC50-based dosing scheme is consistent with observations of
transcriptional responses after dosing curves of small molecules in other human cell lines, as
well. (Srivastan et al., unpublished)

We validated our approach by showing that we could re-identify members of the previously
characterized 7F transcription factor cocktail sufficient for cardiac transdifferentiation of
fibroblasts.(Fu et al., 2013) In particular, we showed that transcription factors that drive a cellular
identity, in this case cardiomyocyte, are highly “perturbable” in cardiomyocytes. Prior to collecting
these results we had hypothesized that the opposite would be true, i.e., that lineage-driving
factors would be less perturbable than other similarly expressed genes. Nonetheless, members of
7F are often up-regulated after several kinds of small molecule perturbation, whereas other
highly-expressed transcription factors are not as frequently up-regulated by many kinds of
perturbations. Following up on this, we developed a new smFISH-based assessment of cardiac
transdifferentiation efficiency and applied it to verify 7F-based transdifferentiation in three types of
human fibroblasts.

We then extended the discovered association between cardiomyocyte lineage-driving capacity of
transcription factors and high perturbability to rational manipulation of fibroblast cell identity. That
is, we identified transcription factors based on their high perturbability in fibroblasts and
hypothesized that for them the inverse of 7F would be true. If 7F overexpression drove cells
toward cardiomyocyte identity, then maybe fibroblast-perturbable factor knockdown could drive
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cells away from fibroblast identity. Therefore, we tested knockdown of 16 fibroblast-perturbable
factors in fibroblasts prior to iPSC reprogramming and observed that 8 of them enhanced the
efficiency of conversion to pluripotency. This success rate, 8/16, is comparable to the validation
rate of the top hits from a pooled screen of reprogramming efficiency enhancement by hundreds
of epigenetic modifiers conducted in the same cell line (9/23 tested; (Cacchiarelli et al., 2015)).

Overall, these results provide insight into both practical and theoretical aspects of the regulation
of cellular identity from two perspectives. First, from a practical, engineering point of view, the P3
experimental design and analysis pipeline could be useful for prioritizing the sets of transcription
factors to overexpress or suppress when developing a new transdifferentiation or reprogramming
protocol. Second, theoretically, we can infer from these results that for maintenance of cell
identity in general, it may be that, in some way, it is useful to reinforce the expression of particular
transcription factors to stabilize larger gene expression programs. Intriguing work in yeast
suggests that in new environments cells can stochastically tune and then reinforce the expression
of fitness-enhancing genes.(Freddolino et al., 2018) Extended to a given cell identity in its niche
in the body, fitness enhancement could come from best fulfilling its needed role in that
niche.(Arendt et al., 2016)

Alternatively, the observation of perturbability in P3 experiments might just be coincidental (and
convenient for engineering) rather than per se functional. If, for example, lineage-driving
transcription factors are downstream of a larger number of signal transduction pathways in a cell
type than non-lineage-driving transcription factors, then perhaps there are therefore more ways to
elicit a differential expression response in these genes.
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In the future, I hope that P3 proves to be useful not only in developing more efficient protocols for
the manipulation of fibroblast and cardiomyocyte cellular identity, but also protocols for
engineering any cell type of interest. Additionally, I look forward to comparing the results of P3
with orthogonal methods for the discovery of factors that enhance directed changes of cellular
identity. For instance, in the Raj lab we have already started an exciting new project, which
combines cellular barcoding and a form of RNA FISH to retrospectively isolate the rare fibroblasts
that go on to successfully reprogram to iPSC after Yamanaka factor induction. It will be
interesting to see if fibroblast-perturbable factors are lower in cells primed to reprogram relative to
cells that are destined to fail to reprogram.

In summary, inoFISH and P3 are two projects that focused on building quantitative models of
gene regulation, each at different scales of biological organization. As such, we needed to
overcome different types of challenges to complete them. In the case of inoFISH, we had a
straightforward, traditional small-scale model of single-cell variability for a small number of
interacting molecules. In the case of P3, however, we were faced with a more complicated
system: the set of all transcription factors. Therefore, we developed an analytical framework that
was not just like an inoFISH-scale model but 1000-times larger. Through the lens of perturbability
we were able to separate out lineage-driving transcription factors from others of similarly high
expression level, and to use them in directed changes of cellular identity. Hopefully these
projects, considered side-by-side, together demonstrate the utility of diverse methods,
experimental designs, and models in the systems biology of gene regulation as this field develops
in a world with access to ever higher-throughput and more precise genetic and biochemical
techniques. (Mellis and Raj, 2015)
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APPENDIX A: STATISTICAL ANALYSIS OF RNA EDITING LEVELS
BASED ON INOFISH EXPERIMENTAL RESULTS
Please note that much of this analysis is based on the Supplementary Note in Levesque, et al.,
2013. This analysis originally appeared in the Supplementary Note of Mellis et al., 2017.

1 DETECTING THE PRESENCE OF ANY RNA EDITING
The most basic question we can answer with inoFISH is whether or not there is any editing at a
given site of interest in a given transcript of interest.
Consider an experiment with T total transcripts of a species of interest expressed across all N
cells observed. Of these T transcripts, we observe OI colocalizing with an Inosine detection probe
spot. Upon pixel-shift analysis, we see that the probability of guide colocalization with an inosine
detection probe spot purely by chance is SI (range 0 - 1).
For simplicity, we will also assume that the editing status detection label (only false-positive here)
of each transcript (of all T transcripts) in an inoFISH experiment is independent of the editing
status label of any other transcript.
Therefore, we can model OI as being drawn from a binomial distribution with parameters SI and
T. Our null hypothesis is that any observed colocalizations are false-positive colocalizations. The
probability of observing at least O =x spots under the null hypothesis is:
I

T
j
P(OI≥x|SI,T)= å Tj⋅SI(1−SI)T−j
j=x

(1)

2 MODELING RNA EDITING LEVELS IN A SINGLE EXPERIMENT
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The next level of detail we might want from an inoFISH experiment is a quantitative estimate of
the editing level of a given site of interest in a given transcript of interest. That is, what fraction of
these transcripts are edited at this site?
Consider an experiment with T total transcripts expressed across all N cells observed. We
observe some number OI of them to be labelled Inosine, i.e., edited, and some fraction OA
labelled Adenosine, i.e., unedited. The remaining U transcripts are unlabelled.

2.1 GOAL: ESIMTATING EDITING LEVEL
We will model the editing level E (range 0 - 1), which is the probability that a transcript in this
population is in fact edited at this point in time. The T total transcripts are composed of TI edited
transcripts and TA unedited transcripts, where TI+TA=T. The editing level of the transcript of
interest at the site of interest is:

TI
E= T (2)
The goal of our analysis, therefore, is to estimate E. Here we outline a framework for calculating a
MLE for Ê, including upper and lower bounds on the confidence interval for Ê.

2.2 MODELING INOFISH DETECTION EFFICIENCY
Since we don’t directly have access to T in an experiment, we need some other way to estimate
I
the fraction in Eq. 2. As outlined above, inoFISH gives us the ability to observe some transcripts
labelled as unedited (OA) and some transcripts labelled as edited (OI). We also know our
expected false-positive colocalization rate for each detection probe through pixel-shift analysis.
The fraction of all T spots colocalizing with Adenosine detection probes after pixel-shift is S . The
A
fraction of all T spots colocalizing with Inosine detection probes after pixel-shift is SI. We will
exploit our measurements of T,O ,O ,S , and S to estimate E.
A I A
I
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Before we do that, however, we have to make assumptions about OA and OI. Specifically, we
need to make an educated guess about whether they equally scale with respect to the true values
they are designed to measure (TA and TI). Formally, we will make assumptions about the probetrue
true true
specific true-positive detection efficiencies, which we will denote as dA and dI . dA is the
true
fraction of all TA unedited transcripts correctly labelled as Adenosine. Similarly, dI
is the
fraction of all TI edited transcripts correctly labelled as Inosine.

2.2.1 A QUICK ILLUSTRATION OF DETECTION EFFICIENCY
true
true
Note that dA and dI
may be equal while OA and OI are not (even if SA=SI, as well). For
example, consider an experiment in which T=100 total transcripts, of which TA=90 and TI=10 and
true true
dA =dI =10%. If SA=SI=2%, then we would expect to observe:

False−positiveAdenosinelabels=

SATA+SATI=0.02(90)+0.02(10)=2

True−positiveAdenosinelabels=

dA TA=0.1(90)=9

true

False−positiveInosinelabels= SITA+SITI=0.02(90)+0.02(10)=2
true

True−positiveInosinelabels= dI TI=0.1(10)=1
Which gives O =2+9=11 and O =2+1=3.
A
I

2.2.2 EMPIRICAL ESTIMATES OF DETECTION EFFICIENCY
In an inoFISH experiment, the fraction of guide spots colocalizing with an Adenosine or Inosine
detection probe spot is the total detection efficiency, dtotal.
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dtotal=

OA+OI
T

We can decompose the detection efficiency into true-positive and false-positive signal. The falsepositive colocalization events are entirely estimated by pixel-shift analysis:

dtotal= dtrue+dfalse
= dtrue+SA+SI
Therefore, in any experiment, we can estimate an overall fraction of likely true-positive
colocalization events:

̂dtrue=

OA+OI
T

−(SA+SI)

This total true-positive fraction can itself be decomposed into Adenosine and Inosine fractions:
true

dtrue=

true

dA TA+dI TI
T

true true
If dA =dI =d,
true

true

d

=

dtrue=

true

dA TA+dI TI
T
d(TA+TI)
T

dtrue=

d(T)
T

⇒̂d=

̂dtrue
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true true
If dA ≠dI =d, the estimation of editing level is a bit more complicated (as we will explore
below).
In the case of the inoFISH-like method SNP FISH (Levesque et al., 2013), which allows for
visualization of genetically encoded single-nucleotide variation in transcripts, we can directly
estimate individual detection probes’ detection efficiencies with homozygous genetic controls.
However, since RNA editing is a post-transcriptional regulatory process, we know of no way to
ensure that all endogenously-transcribed copies of a transcript of interest are edited. This limits
true
true
our ability to directly measure dI
alone. Similarly, we cannot directly measure dA ; ADAR
protein family members, which catalyze RNA editing, often have redundant targets and knockout
of some family members is lethal. Hence, we also cannot directly measure the detection
efficiency of the unedited detection probe on endogenously-transcribed RNAs that are all surely
unedited.
In experiments evaluating genetically-encoded single-nucleotide variation in transcripts, rather
than post-transcriptional single-nucleotide variation, we can design simple panels of controls to
systematically quantify detection efficiencies for each detection probe. In our lab we have
observed detection efficiencies of detection probes in such control experiments ranging from 5%
to 60%. Further, in the majority of probe sets we have examined, the two detection probes have
equal detection efficiencies. In an inoFISH experiment, equal detection efficiencies would mean
true true
that dA =dI . In the few cases where detection efficiencies differ between a probe set’s two
detection probes, we have not observed any differing by more than about 8%.
We will present a statistical framework for calculating Ê and its confidence interval under different
assumptions about the detection efficiencies of inoFISH detection probes.

2.3 MODELING INO FISH EXPERIMENTS
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Our general strategy for finding a MLE and confidence interval bounds on Ê will be to model
inoFISH experiments based on our observations. From this model we can solve for a MLE and
computationally simulate similar experimental observations to draw bounds on the confidence
interval for Ê.

2.3.1 M ODELING INO FISH WITH A MULTINOMIAL
In order to find a MLE, we need a functional form for data likelihood. For simplicity, we will
assume that the editing status of each transcript (of all T transcripts) in an inoFISH experiment is
independent of the editing status of any other transcript’s editing status. Further, we will assume
that whether or not any transcript is detected at all is independent the detection of any other
transcript. Therefore, we can model an inoFISH experiment as T transcripts drawn from a
multinomial with probabilities as follows:

P(OA=x,OI=y|T)=

multinomial(α,β,γ)

Where for any individual transcript r∈T,

α=

P(r∈OA)

β=

P(r∈OI)

γ=

P(r∈U)

2.4 POPULATION-WIDE PARAMETER ESTIMATION
Consider an experiment, as above, with the following findings: Across N cells, there are T total
transcripts of interest, of which OA=x are observed unedited and OI=y are observed edited. Upon
pixel-shift analysis, we see that the probability of false-positive colocalization with Adenosine
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detection probes is SA=sA and the probability of false-positive colocalization with Inosine
true
detection probes is SI=sI. With knowledge of T,OA,OI,SA, and SI, we can also calculate dA
true
and dI , as above.
By the law of conditional probability, since P(r∈TA)+P(r∈TA)=1 for any transcript r,

P(r∈OA)=
=

true

true

−dA E+dA +sA

P(r∈OI)=
=

P(r∈OA|r∈TA)P(r∈TA)+P(r∈OA|r∈TI)P(r∈TI)

P(r∈OI|r∈TI)P(r∈TI)+P(r∈OI|r∈TA)P(r∈TA)

true

dI E+sI

These will be two of our three probability parameters for the multinomial distribution simulating an
inoFISH experiment:
true

true

P(r∈OA)=

−dA E+dA +sA=α

P(r∈OI)=

dI E+sI=β

true

All U=T−OA−OI transcripts not labelled as either Adenosine or Inosine are undetected, so:

P(r∈U)=

1−α−β
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=

true

true

true

(dI −dA )E−dA −sA−sI+1=γ

This means that we can model inoFISH experiments that are consistent with our observations as
follows:

P(OA=x,OI=y|T)=
=

multinomial(α,β,γ)

T!
x y T−x−y
x!y!(T−x−y)!α β γ

We can find the maximum likelihood estimate of E by differentiating the data likelihood with
respect to E and finding the root. Further, since the logarithm is a monotonically increasing
function, we can alternatively solve for the maximum of the log-likelihood (which is simpler in this
case).

0=

∂
T!
x y T−x−y
ln(
)
∂E x!y!(T−x−y)!α β γ

0=

x(−dA ) y(dI ) (T−x−y)(dI −dA )
α + β +
γ

true

true

true

true

From here, we can solve for Ê∈[0,1].

2.4.1 EQUAL DETECTION EFFICIENCIES
true true true
If dA =dI =d
, as is usually the case for probe sets of the sort used in inoFISH, the
functional form of Ê is rather simple:

0=

−xdtrue ydtrue (T−x−y)(0)
α + β +
γ

xdtrue ydtrue
α = β
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true

true

x(dtrueE+sI)= y(−dA E+dA +sA)

Ê=

y(dtrue+sA)−xsI
(xdtrue+ydtrue)

(3)

This result (Eq. 3) makes intuitive sense: it is the fraction of all labelled transcripts observed to be
inosine, correcting for false-positives.
For example, consider a simple experiment in which we have the following observations:

T=100, OA=15, OI=25
Upon pixel-shift analysis, we get:

SA=0.03, SI=0.03
As in section 2.2.2, if we assume equal detection efficiencies we get:

̂dtrue=

̂dtrue=

OA+OI
T

−(SA+SI)

15+25
100 −(0.03+0.03)=0.34

Therefore, in this experiment we get an estimated editing level:

Ê=
=

y(dtrue+sA)−xsI
(xdtrue+ydtrue)
0.647

Note that on first glance the results might suggest an editing level estimate of about
25/(15+25)=0.625. The MLE, however, accounts for false-positive colocalizations as measured by
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pixel-shift for each detection probe channel. In this case, there are the same number of expected
false-positive colocalizations for each detection probe. When these are subtracted out in the
MLE, the proportional difference between OA and OI is accentuated, giving a slightly higher MLE
for editing level (0.647>0.625).

2.4.2 U NEQUAL DETECTION EFFICIENCIES
true true
If dA ≠dI , as has been observed in some cases of probe sets like those used in inoFISH, we
can still solve for a maximum likelihood estimate of E, but the functional form is not as compact.
true

0=

true

true

true

x(−dA ) y(dI ) (T−x−y)(dI −dA )
α + β +
γ
true

true

x(−dA )

true

y(dI )

true

(T−x−y)(dI −dA )

0=

+ true
+ true true
true
true
true
−dA E+dA +sA dI E+sI (dI −dA )E−dA −sA−sI+1

0=

x(−dA )(dI E+sI)((dI −dA )E−dA −sA−sI+1)+

true

true

true

true

true

true

true

true

true

true

true

y(dI )(−dA E+dA +sA)((dI −dA )E−dA −sA−sI+1)+
true

true

true

true

true

(T−x−y)(dI −dA )(−dA E+dA +sA)(dI E+sI)

0=

aE2+bE+c,where

a=

dItrue(−T+x+y) −dAtrue+dItrue dAtrue−xdItrue dAtrue 2+x dItrue 2dAtrue

(

(

) (

)

)

−ydItrue dAtrue 2+y dItrue 2dAtrue
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(

) (

)

b=

(

)

(

)

−ysA dItrue 2+sAdItrue(T−x−y) −dAtrue+dItrue −xdItruedAtrue−ydItruedAtrue+

(

)

2sIxdItruedAtrue+sIydItruedAtrue+xsAdItruedAtrue+2ysAdItruedAtrue−y dItrue 2dAtrue+

(

)

(

)

sI(−T+x+y) −dAtrue+ditrue dAtrue+ditrue(T−x−y) −dAtrue+ditrue dAtrue−

(

)

(

)

(

)2

sIx dAtrue 2+xdItrue dAtrue 2+2ydItrue dAtrue
c=

2

(

)

ysAdItrue−sIysAdItrue−ysAdItrue+sIsA(T−x−y) −dAtrue+dItrue −sIxdAtrue+
2

sI xdAtrue+sIxsAdAtrue+ydItruedAtrue−sIydItruedAtrue−2ysAdItruedAtrue+

(

)

(

)

(

)2

sI(T−x−y) −dAtrue+dItrue dAtrue+sIx dAtrue 2−ydItrue dAtrue

The root that falls within [0,1] will be the physically realizable solution (our Ê). The quadratic
formula gives us the roots:

Ê=

−b±

b2−4ac
2a

(4)

2.5 PERFORMING SIMULATED DETECTION EXPERIMENTS
For a given experiment, we know T,OA,OI,SA, and SI. As discussed above, from here we can
model our experiment with a multinomial distribution. We can simulate the population-wide
results, i.e., OA=x, OI=y, U=T−x−y

, of one such inoFISH experiment by drawing from the

multinomial above according to:

P(OA=x,OI=y|T)=

multinomial(α,β,γ)
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After drawing OA=x, OI=y, U=T−x−y

, we can re-calculate Ê (call this Ê') using the method

above.

2.6 PARAMETRIC BOOTSTRAPPING A CONFIDENCE INTERVAL FOR Ê
We can re-sample from this multinomial distribution many times (e.g., 100000 draws) and
calculate the range of values of Ê' seen in 95% of the samples. This method is known as
parametric bootstrapping.
The 2.5%ile of Ê' is the lower bound ÊLB on the 95% CI for Ê. The 97.5%ile of Ê' is the upper
bound ÊUB on the 95% CI for Ê.

3 MODELING DIFFERENCES BETWEEN RNA EDITING LEVELS
Consider two different inoFISH experiments with sets of population-wide findings
(1) (1) (1) (1)
(2) (2) (2) (2)
{T(1),OA ,OI ,SA ,SI } and {T(2),OA ,OI ,SA ,SI }. Are the estimated editing levels, Ê(1)
and Ê(2), observed in these two experiments different from one another? We can parametrically
bootstrap this, too, as follows.
1. Model both experiments with multinomials, as above. Call these distributions M(1) and M(2).
2. Draw a sample from M(1) and calculate Ê'(1)
3. Draw a sample from M(2) and calculate Ê'(2)
(1) (2)
4. Calculate Ê' −Ê' =δ'. Store this result in the vector Δ'.
5. Repeat steps 2-4 100000 times.
To check the significance level of your favorite difference a, calculate the fraction of entries δ'∈Δ'
that satisfy δ'≥a.
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3.1 BOOTSTRAPPING A CONFIDENCE INTERVAL FOR THE DIFFERENCE BETWEEN EDITING LEVELS
Alternatively, one could just report the 95% CI for the magnitude of the difference Δ between
editing rates between the experiments modeled by M(1) and M(2). The lower bound of this CI
ΔLB is the 2.5%ile of Δ'. The upper bound of this CI ΔUB is the 97.5%ile of Δ'.

4 INCORPORATING MULTIPLE INOFISH EXPERIMENTAL REPLICATES
In order to have a more accurate estimate of the editing rate, we care about the average editing
rate across multiple replicates. The following strategy for estimating average editing level across
multiple replicates can be applied to any number of replicates, R.
(1) (1) (1) (1)
For example, if we have three replicates (R=3) with results: {T(1),OA ,OI ,SA ,SI },
(2) (2) (2) (2)
(3) (3) (3) (3)
{T(2),OA ,OI ,SA ,SI }, and {T(3),OA ,OI ,SA ,SI }. We think that the mean of the editing
levels across these three replicates is a good summary statistic for describing the editing level in
the biological and experimental conditions we are observing.

Ē=mean(E(1),E(2),E(3)) (5)
Our maximum likelihood estimate of Ē is simply the mean of the editing rate across all three
replicates, ̂Ē. We can draw a confidence interval on ̂Ē using a similar algorithm to an individual Ê.
In the case of averaging over three replicates:

1. Model all three experiments with multinomials, as above. Call these distributions M
and M(3).
2. Draw a sample from M(1) and calculate Ê'(1)
3. Draw a sample from M

(2)

(2)
and calculate Ê'
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(1)

,M

(2)

,

4. Draw a sample from M(3) and calculate Ê'(3)
5. Calculate the mean of these draws: ̂Ē'=mean(Ê'(1),Ê'(2),Ê'(3)). Store this result.
6. Repeat steps 2-5 100000 times.
As above, the 2.5%ile is the lower bound on the confidence interval, Ē
̂ 'LB. The 97.5%ile is the
upper bound on the confidence interval, ̂Ē' .
UB

4.1 ALTERNATIVE SUMMARY STATISTICS ON EXPERIMENTAL REPLICATE RESULTS
One might also reasonably want to report statistics on editing levels across multiple replicates
other than the mean. For example,
1. The maximum might help you better understand if the editing level of the site of interest
saturates at a given percentage in these experimental conditions.
2. The median editing level across multiple replicates may be a more stable average value if you
want to de-emphasize outlying results.
3. The sample variance would give insight into the variability between replicates.
In order to use these, or any other summary statistics on replicate editing levels, substitute that
statistic in step 5 of the algorithm in Section 4.

4.2 DETECTING DIFFERENCES IN SUMMARY STATISTICS WITH MULTIPLE REPLICATES IN TWO
CONDITIONS

To bring our population-wide analyses to a close, let’s integrate multiple experimental replicates
across multiple conditions. In a toy case, let’s work with C=2 conditions, each with R=3 replicates.
We want to know if the mean editing rates are significantly different from each other Ē(1)−Ē(2)=̄Δ.
As above, we can model each replicate j∈{1,2,3} in each condition i∈{1,2} with R⋅C=6
multinomials Mi,j .
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Our estimate of ̄Δ is ̂̄Δ=̂Ē(1)−̂Ē(2). As above, we can use parametric bootstrapping to draw a
confidence interval around this estimate or to check its significance.
1. Model all experiments with multinomials, as above. Call these distributions M(1,1) , M(1,2) ,
M

(1,3)

,M

(2,1)

,M

(2,2)

,M

(2,3)

.

2. Draw a samples from condition 1 models M(1,1) , M(1,2) , M(1,3)

and calculate ̂Ē'(1)

3. Draw a samples from condition 2 models M(2,1) , M(2,2) , M(2,3)

and calculate ̂Ē'(2)

4. Calculate ̂Ē'(1)−̂Ē'(2)=̄δ'. Store this result in the vector ̄Δ'.
5. Repeat steps 2-5 100000 times.
As above, the 2.5%ile is the lower bound on the confidence interval, ̄Δ
̂ LB. The 97.5%ile is the
upper bound on the confidence interval, ̂̄Δ .
UB

5 SINGLE-CELL EDITING LEVEL ANALYSIS
inoFISH also enables quantitative analysis of editing levels with single-cell resolution. The most
obvious question we might ask about editing levels in single cells is whether all cells in the
population appear to have the same editing level, or if they instead appear to have different
editing levels.
Each cell has a variable and relatively small number of transcripts. Therefore our resolution of
single-cell editing levels is much more limited than population-wide. However, if we make a
simplifying assumption, we can nonetheless use our inoFISH data to answer this question. In
particular, we will assume that all of our labels are true-positive.
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Consider an experiment with N cells and population-wide measurements as above, along with an
(i)
estimate of population-wide editing level Ê. For i∈{1,...,N}, celli has OI transcripts labelled as
(i)
(i) (i) (i)
edited and OA labelled as unedited. Call OT =OI +OA .
If all N cells have the same level of editing, then each cell’s count of labelled edited transcripts
(i)
(i)
(OI ) will appear to be drawn from a binomial distribution with parameters OT and Ê. The data
likelihood of observing these results in all N cells is:

N
N (i) (i) (i)
(i)
(i)
(i) (i)
P(D|τ)= Õ P(OI |OT ,Ê)= Õ OT OI ÊOI (1−Ê)OT −OI
i=1
i=1

(6)

We can use this formula to bootstrap a distribution for data likelihood values (as in previous
sections). If the observed value of P(D|τ) falls outside of the bulk of the simulated values, then we
can conclude that the experimental results are unlikely to come from our simple binomial model.
That is, some other source of variability must also contribute to our results. The most intuitive
explanation for this is that there is some cell-to-cell difference in editing level.
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APPENDIX B: MATERIALS AND METHODS FOR CHAPTER 1
InoFISH protocol.
The step-by-step inoFISH protocol (description below) can be found
https://media.nature.com/original/nature-assets/nmeth/journal/v14/n8/extref/nmeth.4332-S3.pdf.
Cell culture. We grew human neuroblastoma cells (SH-SY5Y, ATCC CRL- 2266) in a 1:1 mixture
of Eagle’s Minimum Essential Medium and F12 Medium supplemented with 10% FBS and 50
U/mL penicillin and streptomycin. We grew human glioblastoma cells (U-87 MG, ATCC HTB-14)
in Eagle’s Minimum Essential Medium supplemented with 10% FBS and 50 U/mL penicillin and
streptomycin. Note: Some SH-SY5Y and U87 cells can be autofluorescent when grown on glass
slides, this is improved when the cells are ~70% confluent.
Verification of RNA editing of candidate targets. As described below, we used RT-PCR of total
RNA and PCR of genomic DNA in cell lines of interest to further check that candidate editing sites
were in fact RNA edited in our cell lines.
Optimization of inoFISH targets. We then chose targets for inoFISH by checking RT-PCR and
genomic DNA PCR Sanger sequencing results for each candidate site to ensure that there would
be no additional polymorphisms in transcripts, resulting either from RNA editing or singlenucleotide polymorphisms, in the regions flanking the editing site up to 30-bp up- or downstream.
We ultimately designed inoFISH probe sets against one editing site in NUP43 and two editing
sites in EIF2AK2 (both using the same guide probe set) that appeared to be amenable to inoFISH
guide and detection probe set design. We were able to verify inoFISH probe binding with
detection efficiencies greater than expected by random colocalization for the one NUP43
candidate editing site and one of the two EIF2AK2 editing sites. (See below for experimental
methods.)
Genotyping of edited regions. We extracted genomic DNA from SH-SY5Y cells and U-87 MG
cells using the Qiagen DNeasy Blood & Tissue kit. We used Platinum Taq (Invitrogen cat.
#10966-018) for PCR amplification of the genomic regions of interest for each target, following
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manufacturer’s recommendations for reaction component concentrations. We PCR-amplified two
biological replicates, each with two technical PCR replicates. For GRIA2, we used primers
GRIA2-F1 and GRIA2-R2 (Table 1.1). For EIF2AK2, we used EIF2AK2_20-F1 and EIF2AK2_20R1, and for NUP43 we used NUP43-F1 and NUP43-R1 (Table 1.1). We confirmed PCR product
sizes by gel electrophoresis, using a 1.5% agarose gel in TAE. Then, we treated these PCR
products with ExoSAP-IT (Affymetrix 78200) according to manufacturer’s instructions, and
submitted them for Sanger sequencing at the University of Pennsylvania DNA Sequencing
facility.
Estimation of editing efficiency by RT-PCR and Sanger sequencing. We extracted total RNA
from SH-SY5Y and U-87 MG cells using miRNeasy kits (Qiagen 217004) according to
manufacturer’s instructions. Then, we reverse-transcribed target transcripts around editing sites
of interest using Superscript III First strand RT kit (ThermoFisher 18080044) according to
manufacturer’s instructions. In separate reactions for RNA from each cell type, we used both
oligo-dT and transcript-specific primers for reverse-transcription. Briefly, we used 50 ng of RNA
per reaction for reverse transcribed with either oligo-dT or transcript-specific primers (Table 1.1).
Then, we performed PCR with transcript-specific primers (Table 1.1) using Platinum Taq
(Invitrogen cat. #10966-018) according to manufacturer’s instructions. We completed biological
replicates, each with technical PCR replicates for these reactions. We confirmed product sizes by
gel electrophoresis on 1.5% agarose gels in TAE. Then, we treated these products with ExoSAPIT (Affymetrix 78200) according to manufacturer’s instructions and submitted for sequencing at
the University of Pennsylvania DNA Sequencing facility.
Estimation of editing efficiency by clonal analysis of GRIA2 RT-PCR product. The amplified
GRIA2 cDNA was cloned into a vector using the TOPO TA cloning kit (Thermo), transformed into
chemically competent Escherichia coli cells, and plated on LB plates with 0.1 mg/mL ampicillin.
We isolated DNA from >20 Individual colonies and submitted it for sequencing at the University of
Pennsylvania DNA Sequencing Facility. We performed sequence alignment at the editing site
using MAFFT in Benchling to determine the ratio of edited and unedited transcripts.
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Estimation of editing efficiency by restriction digest and bioanalyzer analysis. Edited and
unedited GRIA2 cDNAs yield distinct restriction fragment patterns upon digestion with BbvI
(Whitney et al., 2008). Edited GRIA2 cDNA yields two DNA fragments upon digestion (225 bp
and 46 bp), and unedited GRIA2 cDNA yields three DNA fragments (145 bp, 80 bp, and 46 bp).
Following BbvI digestion (NEB R0173S) of GRIA2 cDNA, according to manufacturer’s
instructions, we submitted digestion products for fragment sizing analysis on an Agilent 2100
Bioanalyzer at the University of Pennsylvania DNA Sequencing Facility.
RNA probe design and synthesis. For each of the validated editing sites, we designed probes
by matching free energies of hybridization as specified in Levesque et al. (2013b). We optimized
mask oligonucleotides to leave 8-base-pair (bp) overhangs for each of the detection probes and
pooled all five together to act as the complete allele-specific probe. We provide all oligonucleotide
sequences in Table 1.1. We coupled 3’ amine-labeled adenosine- and inosine-detection probes
to NHS-Cy3 or NHS-Cy5 fluorophores (GE Healthcare) and purchased respective guide probes
labeled with Cal fluor 610 (Biosearch Technologies). We coupled probes targeting ADAR1,
ADAR2 and NEAT1 mRNA to NHS-Atto700. We purified dye-coupled probes by highperformance liquid chromatography.
inoFISH procedure. We grew cells on glass coverslides until ~70% confluent. We washed the
cells twice with 1X PBS, then fixed for 10 minutes with 4% formaldehyde/1X PBS at room
temperature. We aspirated off the formaldehyde, and rinsed twice with 1X PBS prior to adding
70% ethanol for storage at 4°C or inoFISH after a one hour permeabilization in 70% ethanol. We
incubated our cells overnight at 37°C in hybridization buffer (10% dextran sulfate, 2× SSC, 10%
formamide) with 100 nM concentration of guide probe, 24 nM concentration of the adenosineand inosine-detection probes and 72 nM concentration of the mask probe, ensuring excess mask
for complete hybridization to the detection probes. The following morning, we performed two
washes in wash buffer (2X SSC, 10% formamide), each consisting of a 30-min incubation at
37°C. After the second wash, we rinsed once with 2X SCC/DAPI and once with anti-fade buffer
(10 mM Tris (pH 8.0), 2X SSC, 1% w/v glucose). Finally, we mounted the sample for imaging in
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an anti-fade buffer with catalase and glucose oxidase (Raj et al. 2008) to prevent photobleaching.
We performed RNA FISH on cell culture samples grown on a Lab-Tek chambered coverglass
using 50 μL of hybridization solution spread into a thin layer with a coverslip and placed in a
parafilm-covered culture dish with a moistened Kimwipe to prevent excessive evaporation.
Imaging. We imaged each samples on a Nikon Ti-E inverted fluorescence microscope using a
100× Plan-Apo objective (numerical aperture of 1.40) and a cooled CCD camera (Andor iKon
934). For 100× imaging, we acquired z-stacks (0.3 µm spacing between stacks) of stained cells in
five different fluorescence channels using filter sets for DAPI, Cy3, Calfluor 610, Cy5, and Atto
700. The filter sets we used were 31000v2 (Chroma), 41028 (Chroma), SP102v1 (Chroma),17
SP104v2 (Chroma) and SP105 (Chroma) for DAPI, Atto 488, Cy3, Atto 647N/Cy5 and Atto 700,
respectively. A custom filter set was used for Alexa 594/CalFluor610 (Omega). We tuned the
exposure times depending on the dyes used: 4 seconds for each guide probe, 4000 msec for
each of the detection probes, 5000 msec for the NEAT1 probe, and 7000 msec for ADAR1 and
ADAR2 probes. We also acquired images in the Atto 488 channel with a 1000 msec exposure as
a marker of autofluorescence.
Image analysis. We first segmented and thresholded images using a custom Matlab software
suite (downloadable at https://bitbucket.org/arjunrajlaboratory/rajlabimagetools/wiki/Home).
Segmentation of cells was done manually by drawing a boundary around non-overlapping cells.
The software then fits each spot to a two-dimensional Gaussian profile specifically on the Z-plane
on which it occurs in order to ascertain subpixel-resolution spot locations. Colocalization took
place in two stages: In the first stage, guide spots searched for the nearest-neighbor detection
probes within a 2.5-pixel (360-nm) window. We ascertained the median displacement vector field
for each match and subsequently used it to correct for chromatic aberrations. After this correction,
we used a more stringent 1.5-pixel (195-nm) radius to make the final determination of
colocalization. In order to test random colocalization due to spots occurring randomly by chance,
we took our images and shifted the guide channel by adding 5 pixels (1.3 µm) to the X and Y
coordinates and then performing colocalization analysis.
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Autofluorescence subtraction. For U-87 MG cells, we controlled for punctate autofluorescence
by imaging with the 41028 (Chroma) filter set, the ‘gfp channel’, which we have previously found
to be sensitive for autofluorescence in this cell line (data not shown). We performed colocalization
as previously described between guide spots and any spot-like autofluorescence called in the gfp
channel. In R, we excluded spots colocalizing with this autofluorescence from all inoFISH
analyses.
Subcellular localization. Nuclear localization. We extracted a DAPI nuclear mask as previously
described (Raj et al., 2008). We call a spot as localized to the nucleus if the guide spot X and Y
coordinates overlap with the 2D nuclear mask.
Localization to transcription sites. We visualized NUP43 introns by probing with intron-specific
probes coupled to Atto 700 and imaging with SP105 filter set. We used the txnSiteGUI2 interface
within rajlabimagetools to manually curate calls of exon-intron spot colocalization.
Localization to paraspeckles. We visualized paraspeckles by probing with NEAT1-specific probes
coupled to Atto 700 and imaging with SP105 filter set. We used the txnSiteGUI2 interface within
rajlabimagetools to manually curate calls of transcript-paraspeckle association.
In situ cyanoethylation. Cyanoethylation was performed similarly to previous descriptions
(Sakurai et al., 2010; Yoshida and Ukita, 1968). We aspirated the 70% ethanol off of the fixed
cells and added cyanoethylation solution (1.1 M triethylammoniumacetate (pH 8.6) resuspended
in 100% ethanol) with or without 1.6 M acrylonitrile at 70 °C for 15 min. Use large volume to
prevent drying from evaporation. Remove from heat after 15 min (30 min incubation abolishes
guide probe signal) and wash twice with wash buffer (2× SSC, 10% formamide) before beginning
inoFISH procedure.
Statistical analysis. Detection efficiency. For each label (edited or unedited) in each experiment
we calculated the mean fraction of transcripts colocalized with a spot of that label over all
replicates (excluding 3-color spots). For complete details of this analysis, please see Appendix A.
Population-wide editing level estimation by inoFISH. We define the population-wide editing level
estimate as the average over all replicates of the inferred fraction of uniquely labelled guide spots
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labelled as edited. For a complete description of our estimation of population-wide editing level,
please see the Supplementary Note.
Paraspeckle-transcript association rates. In MATLAB, we simulated the exact conditional null
distribution of paraspeckle-transcript association rates for each experiment under the null
hypothesis that a paraspeckle and a nuclear-localized transcript will only colocalize by chance.
For each cell in each experiment, we conditioned on (1) the shape and size of that cell’s nucleus,
(2) the locations of all paraspeckles in that nucleus, and (3) the number of transcripts of interest
(GRIA2 or EIF2AK2) retained in the nucleus. In order to efficiently simulate these distributions,
rather than using txnSiteGUI2 as above, we generated 2D masks for paraspeckle locations and
called paraspeckle-transcript association when a randomly placed transcript spot overlapped with
this mask. We selected the mask size as 25 pixels per paraspeckle spot called--roughly the mean
paraspeckle size--based on our inspection of paraspeckles while calling spots (as in Image
analysis). For each experiment, we simulated draws from the exact conditional null distribution
1000 times. A raw p-value for paraspeckle-transcript association rate is equal to the fraction of
simulations with a higher paraspeckle-transcript association rate. We similarly simulated exact
conditional null distributions for paraspeckle-edited-transcript and paraspeckle-unedited-transcript
association rates.
Single-cell editing level distributions. In R, we assessed single-cell spot counts after inoFISH
colocalization as reported by rajlabimagetools
(https://bitbucket.org/arjunrajlaboratory/rajlabimagetools/wiki/Home; in Image analysis), as well as
after autofluorescence subtraction (for U-87 MG data). We simulated the null distribution of data
likelihood under a null model wherein all cells sharing the same effective editing level: for an
experiment with overall estimated editing level equal to pe (above), let nej be the number of edited
transcripts detected in cell j and nuj be the number the number of unedited transcripts detected in
cell j. Under the null model, nej is drawn from a Binomial with (nej + nuj) draws and probability pe.
We simulated single-cell label counts for cells by drawing from these conditional null distributions
for each cell 100000 times. We then compared the negative log-likelihood of the observed data,
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combined over all replicates, with the distribution of negative log-likelihoods of each simulation
iteration. A p-value of 0.12 indicates that 12% of the simulated iterations had a negative loglikelihood that was greater than the observed data. Note that the -log(likelihood) density plots in
Fig. 3 are subsampled to 3000 of the aforementioned 100000 such iterations per plot, in order to
facilitate figure generation. For complete details of this analysis, please see the Supplementary
Note.
siRNA knockdowns of ADAR2. Briefly, we used Lipofectamine RNAimax to transfect SH-SY5Y
cells with Silencer Select siRNAs targeting ADARB1 (ADAR; ID:s1011, Ambion) and a Negative
Control siRNA (#1, Ambion) for 72 hrs, verifying knockdown via RNA FISH of ADAR2.
SFPQ-guided GRIA2 inoFISH. We performed GRIA2 inoFISH, as described above, but
substituted a smFISH probe set for SFPQ (Cabili et al., 2015) for the GRIA2 guide. Like GRIA2
transcripts, SFPQ transcripts are localized to the nucleus in SH-SY5Y cells. In parallel we
performed regular GRIA2 inoFISH on a sample of cells from the same passage. We counted the
number of GRIA2 mRNA per cell in the regular sample, and subsampled the SFPQ “guide” spots
from that distribution of mRNA counts per cell. In this way, we could more directly compare
colocalization rates with GRIA2 detection probes between SFPQ-guided and GRIA2-guided
experiments. We then performed colocalization as described above.
Cell cycle inhibitor. We measured nuclear retention of GRIA2 mRNA by inhibiting transcription
for 24 hr by applying aphidicolin at 1 ug/ml.
Reproducible analyses. Scripts for all analyses presented in this paper, including all data
extraction, processing, and graphing steps are freely accessible at the following url:
https://www.dropbox.com/sh/j5umuneita1nck9/AAA4W4I648glUUhePJfXyaRaa?dl=0 .
All imaging and other non-RNA-sequencing data associated with this paper are also freely
available at the following url:
https://www.dropbox.com/sh/vwwnwrmgg72o75c/AACsFK6VbJHY2S5MK8JLR2JNa?dl=0 . For
publicly available RNA-seq data discussed in Supp. Fig. 1, please see EBI ArrayExpress
(https://www.ebi.ac.uk/arrayexpress/) accession numbers E-MTAB-2690 (SH-SY5Y samples
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“SY5Y_A” and “SY5Y_B”) and E-MTAB-1875 (U-87 MG samples “s_2_78”, “s_2_82”, and
“s_2_88”).
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APPENDIX C: MATERIALS AND METHODS FOR CHAPTER 2
Cell culture
Unless otherwise noted, all cell culture incubations below were performed at 37°C, 5% CO2. We
tested intermittently for mycoplasma contamination.
GM00942 human dermal fibroblast culture
We cultured GM00942 human dermal fibroblasts (Coriell, GM00942; XX donor, normal-appearing
tissue) according to the distributor’s instructions, on tissue culture-treated dishes in E-MEM (QBI
112-018-101) + 10% FBS (Life Technologies 16000044, lot 1802004) + Pen/Strep.
GM11169 human cardiac fibroblast culture
We cultured GM11169 human cardiac fibroblasts (Coriell, GM11169; XX donor) on tissue culturetreated dishes in DMEM w/Glutamax + 9% FBS (Life Technologies 16000044) + P/S.
HEK293FT culture
We expanded HEK293FT cells in DMEM w/Glutamax + 9% FBS + P/S.
hiF-T culture
We cultured hiF-T cells as previously described prior to hiF-T-iPSC reprogramming
experiments(Cacchiarelli et al., 2015). Briefly, we expanded hiF-T cells in growth medium on TC
plastic dishes coated with Attachment Factor (Fisher S006100), and split cells 1:3 when they
reached 60-70% confluency. hiF-T growth medium (GM) is DMEM/F-12 w/ Glutamax (Life Tech.
10565018) + 10% ES-FBS (Life Tech. 16141079) + 1x 2-Mercaptoethanol (Life Tech. 21985023)
+ 1x NEAA (Invitrogen 11140050) + P/S + 0.5µg/mL Puromycin + 16ng/mL rhFGF-basic
(Promega G5071).
Immortalized human cardiac fibroblast (immHCF) culture
We cultured human immortalized human cardiac fibroblasts (HCFs) as previously
described(Mohamed et al., 2017). We received HCFs from Deepak Srivastava. In brief, we
expanded HCFs on gelatin-coated (Millipore ES-006-B) tissue culture dishes in iCM medium (per
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500mL: 350mL DMEM w/Glutamax + 85mL Medium 199 + 50mL FBS + 5mL Non-essential
amino acids + 10mL Pen/strep).
Platinum-A (Plat-A) retroviral packaging cell line culture
We cultured Platinum-A cells (Cell Biolabs RV-102) according to the manufacturer’s instructions.
We expanded these cells in DMEM w/Glutamax + 9% FBS + P/S + 10ug/mL Blasticidin + 1ug/mL
Puromycin.

Cellular reprogramming
Derivation of cardiomyocytes (iCards) from GM942-iPSCs
We derived cardiomyocytes from GM942-iPSCs, called iCard-942 cells, as previously
described(Laflamme et al., 2007; Palpant et al., 2015; Zhu et al., 2010, 2011). Briefly:
Seeding of GM942-iPSCs
We thawed GM942-iPSCs and grew them in feeder-free conditions on Geltrex-coated
(ThermoFisher, cat. A1413301) dishes in iPS-Brew (Miltenyi, cat. 130-104-368) for 4-5 days, until
~75% confluency. Then, we split and seeded GM942-iPSCs into Geltrex-coated 12-well plates at
a density of roughly 1e6 cells per well in iPS-Brew + 2µM Thiazovivin (Sigma, cat. SML10455MG). After 24 hours, we changed the culture medium to iPS-Brew + 1µM Chiron 99021
(Cayman Chemical, cat. 13122) and then incubated the cells for a further 24 hours.
Differentiation to iCard-942 cells
Starting on Day 0, we incubated GM942-iPSCs for 18 hours in RPMI (Life Technologies, cat.
11875-119) + 100ng/ml Activin A (R&D systems, cat. 338-AC- 010) + 2% B-27 (minus insulin; Life
Technologies, cat. 17504-044). Next, on Day 1 we changed the medium to RPMI + 2% B-27
(minus insulin) + 5ng/ml BMP4 (Peprotech, cat. AF-120-05ET) + 1uM Chiron 99021 and
incubated these cells for 48 hours. On day 3 we changed the medium to RPMI + 2% B-27 (minus
insulin) + 1uM Xav 939 (Tocris Bioscience, cat. 3748) and incubated cells for 48 hours. On Day 5
we changed the medium to RPMI + 2% B-27 (minus insulin) and incubated the cells for 72 hours.
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From Day 8 - 12 we changed the medium to RPMI + 2% B-27 (including insulin) + 1% pen/strep,
and replaced medium every other day.
Glucose-free medium selection steps for cardiomyocytes
In order to enrich the culture for cardiomyocytes, we subjected these cells to two glucose-free
selection steps. On Day 12 we started the first selection step by replacing the medium with RPMI
glucose free (ThermoFisher, cat. 11879020) + 2% B-27 (including insulin) + 1% Pen-Strep and
incubated for 72 hours. On day 15 we replated the cells onto Geltrex-coated dishes at 6.3e5
cells/cm2 in RPMI + 20% FBS (Seradigm, lot 050B14) + 1uM Thiazovivin and incubated them for
24 hours. On Day 16 we changed the medium to RPMI + 2% B-27 (including insulin) and
incubated them for 48 hours to recover. On Day 18 we started the second selection step, again
by replacing the medium with RPMI glucose free (ThermoFisher, cat. 11879020) + 2% B-27
(including insulin) + 1% Pen-Strep and incubated for 72 hours.
Splitting iCard-942 cells into 96-well plates
On Day 21 we split the double-selected iCard-942 cells into Geltrex-coated 96-well plates at a
density of 1e5 cells per well in RPMI + 20%FBS + 1µM thiazovivin and incubated overnight. On
Day 22 we changed the medium to RPMI + 2% B-27 (with insulin) + pen/strep and incubated for
48 hours. By Day 23 or 24 we expected to observe recovery of beating activity among a majority
of the cardiomyocytes in all of the wells. If we did not observe beating activity we changed the
RPMI + 2% B-27 (with insulin) + pen/strep medium on Day 24, incubated for another 48 hours,
and checked again for beating activity on Day 26. If the cardiomyocytes did not regain beating
activity by Day 26 we did not proceed to perturbation culture.

Perturbation culture
GM00942 fibroblasts
For GM00942 fibroblasts, we called the day on which they were seeded in 96-well plates Day -2
of perturbation. We split 95% confluent 10cm tissue culture-treated dishes of cells into 96-well
plates at a density of roughly ~1.5e4 cells per well in EMEM + 10% FBS + Pen/strep and
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incubated for 48 hours. On Day 0 we replaced the medium (250 µL) in each well and added 0.7
µL of drug stock in DMSO (see Table 2.1) or of DMSO (for control cultures). This kept total
DMSO concentration of the perturbation culture medium below 0.3% for all conditions. We
incubated cells for 48 hours, and then on Day 2 replaced medium and re-adding a fresh dose of
drug stock at the same volumes as Day 0. We incubated cells for a further 48 hours before taking
images of each well (below) and extracting RNA (below) on Day 4.
iCard-942
For iCard-942 cells, we called the first day on which we observed beating activity in the majority
of wells of each 96-well plate Day 0 of perturbation. On Day 0 we replaced the medium with
250µL RPMI + 2% B-27 (with insulin) + pen/strep and added 0.7µL of drug stock in DMSO (See
Table 2.1) or of DMSO (for control cultures), again keeping total DMSO concentration of
perturbation culture medium below 0.3% for all conditions. We incubated cells for 48 hours, and
then on Day 2 replaced medium and re-adding a fresh dose of drug stock at the same volumes
as Day 0. We incubated cells for a further 48 hours before taking videos of each well (below) and
extracting RNA (below) on Day 4.
Transdifferentiation of immortalized HCFs to induced cardiomyocyte-like cells
We performed transdifferentiation of immortalized HCFs to induced cardiomyocyte-like cells
(iCMs) as previously described(Mohamed et al., 2017). Briefly, on day -3 we plated HCFs in 12well culture vessels (indicated cell number per experiment) in iCM medium and Plat-A cells in
10cm dishes (4e6 cells per dish) in DMEM w/Glutamax + 9% FBS without any antibiotics. On day
-2 we transfected each dish of Plat-A cells with 10ug of one indicated pMXs expression plasmid
in 500uL Optimem + 35uL Fugene HD. On day 0, we collected viral supernatants and pooled
them as needed for replicate conditions, filtered them through 0.45µm filter units, and transduced
HCFs. For transductions we used 6µg/mL polybrene, a 30min 930 x g spin, and overnight
incubation at 37C. On day 1 we replaced transduction medium with iCM medium. On day 4 we
replaced iCM medium with 75% iCM medium/25% Reprogramming medium (RPMI 1640 + B-27
+ P/S), on day 7 with 50% iCM medium/50% Reprogramming medium, on day 11 with 25% iCM
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medium/75% Reprogramming medium, and on day 14 with Reprogramming medium alone. We
then changed reprogramming medium daily until analysis on the indicated day per experiment,
usually day 24. On day 24, we fixed cells in two formats for analysis. Some 12-well TC plastic
wells were fixed in place using 3.7% formaldehyde and permeablized at least overnight with 70%
Ethanol in 4C, while others were dissociated with Accutase and transferred to Concanavalincoated (Sigma C0412) 8-well Lab-Tek chambers. After 90-120 minutes, transferred samples were
fixed in these 8-well chambers using 3.7% formaldehyde and permeablized at least overnight with
70% Ethanol in 4C. Samples in 12-well wells were processed for FISH imaging by excising them
from their 12-well plate after fixation with a heated 20mm cork borer and processing them for
FISH or immunofluorescence as described below.
Cloning of transcription factor genes and TurboGFP into pMXs
In order to drive overexpression of perturbable transcription factor genes and TurboGFP, we
cloned cDNA for genes of interest into pMXs-gw (Addgene 18656; a gift from Shinya Yamanaka)
using BP and LR Clonase II (Invitrogen). We amplified cDNA of targets of interest using attBtarget-specific primers (Table 2.2). We used standard tools to verify sequence identity of the
plasmid backbone and gene insert, such as restriction digestion and Sanger sequencing. We
amplified attB-TurboGFP off of the SHC003 plasmid (Sigma SHC003).
Indirect functional titering of pMXs retroviral vectors
Since our expression vectors do not contain selectable or fluorescent markers and pMXs
retroviral vectors only transduce dividing cells, we indirectly titered each experimental replicate’s
batch of virus by co-transducing parallel samples of HCFs with pMXs-DsRed Express (Addgene
22724; a gift from Shinya Yamanaka) and pMXs-TurboGFP (see “Cloning” above) produced
using the same batch of Plat-A cells under the same conditions. In order to estimate the fraction
of cells that are infected at least once per factor, we considered the infection rates of these
fluorescent pMXs vectors. By comparing the fraction that are co-infected with both against the
fraction that are infected with each factor at all, we can infer the fraction of cells dividing in the
population during the transduction period and the fraction of those cells that receive at least one
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copy of any individual expression vector. We make the simplifying assumption that among
dividing cells infection events are independent of each other. Therefore, the ratio of the fraction
that are DsRed+ and GFP+ to the fraction that are DsRed+ (or GFP+) is approximately the
square of the transduction rate for any individual virus. E.g., for 30% of cells being DsRed+ and
24.3% being DsRed+ and GFP+, 24.3/30 = 0.81, which gives 90% transduction rate for each
individual virus.
shRNA-based knockdown of transcription factors in hiF-T cells
We conducted knockdown of individual transcription factors using shRNAs essentially as
previously described.(Cacchiarelli et al., 2015) In brief, we acquired cloned pLKO.1, pLKO.1shRNA, and pLKO.1-TurboGFP plasmids from the University of Pennsylvania High-Throughput
Screening Core (Table 2.3). We verified shRNA and backbone sequence with Sanger
sequencing. We packaged shRNA lentivirus using pMD2.G (Addgene 12259; a gift from Didier
Trono) and psPAX2 (Addgene 12260; a gift from Didier Trono) in HEK293FT cells, and filtered
viral supernatant through 0.22µm filter units prior to infecting hiF-T cells. We infected hiF-T cells
at an MOI of approximately 1 (for a transduction efficiency of ~70%) with 4µg/mL polybrene and
30 min 930 x g centrifugation. Since hiF-T cells are already Puromycin-resistant, we were unable
to perform an antibiotic selection step after infection with these pLKO.1-puro-based shRNA
plasmids.
Verification of knockdown efficiency following shRNA transduction
We performed RT-qPCR on RNA extracted from samples of the hiF-T cells that we used in
reprogramming experiments. We used Superscript III Reverse Transcriptase for first-strand cDNA
synthesis and Power SYBR qPCR Master Mix with gene-specific primer pairs for qPCR on an
Applied Biosystems 7300 system. We performed all statistical analysis using custom scripts in R
(see “Code accessibility” below for all scripts) and calculated knockdown efficiency using the
ΔΔCt method.

hiF-T reprogramming to pluripotency
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We performed hiF-T reprogramming experiments as previously described. Briefly, after shRNA
transduction on day -7, we expanded cells in hiF-T GM without puromycin for one week. On Day 1 we seeded CF-1 Irradiated MEFs on uncoated 24-well plates (Corning) at a density of 2.5e5
cells per well in hiF-T GM without puro. On Day 0, we seeded 104 hiF-T cells per 24-well plate
well. On Day 1 we began Yamanaka factor induction by switching media to hiF-T GM with
2µg/mL doxycycline and without puromycin. On Day 3 we switched media to KSR Medium
(KSRM): DMEM/F-12 w/ Glutamax (Life Tech. 10565018) + 20% Knockout Serum Replacement
(Life Tech. 10828010) + 1x 2-Mercaptoethanol (Life Tech. 21985023) + 1x NEAA (Invitrogen
11140050) + P/S + 8ng/mL rhFGF-basic + 2µg/mL Doxycyclin. We changed KSRM daily, and
analyzed cells on day 21.

High-throughput RNA extraction
We used RNaqueous-96 kits (Ambion AM1920) for RNA extraction without the optional DNase
step, according to manufacturer’s instructions.

RNAtag sequencing
We conducted highly parallelized bulk RNA sequencing with RNAtag-seq as previously
described, using all components and steps in the published protocol.(Shishkin et al., 2015) We
ordered the specified 32 barcoded DNA oligos for RNAtags from Biosearch Technologies and
indexed primers for library amplification and reverse transcription from IDT. We sequenced all
RNAtag-seq libraries in batches of 96 samples on an Illumina NextSeq 550 using 75 cycle highoutput kits (Illumina 20024906).

RNAtag-seq data processing
We demultiplexed RNAtag-seq reads using custom scripts, courtesy of Edward Wallace.(Wallace
and Beggs, 2017) We aligned RNAtag-seq reads to the human genome (hg19) with STAR
v2.5.2a and counted uniquely mapping reads with HTSeq v0.6.1.(Shaffer et al., 2017) We
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performed all downstream analysis in R v3.6.1 using packages yaml_2.2.0, DESeq2_1.24.0,
SummarizedExperiment_1.14.0, DelayedArray_0.10.0, BiocParallel_1.18.0, matrixStats_0.54.0,
Biobase_2.44.0, GenomicRanges_1.36.0, GenomeInfoDb_1.20.0, IRanges_2.18.1,
S4Vectors_0.22.0, BiocGenerics_0.30.0, e1071_1.7-2, magrittr_1.5, ggrepel_0.8.1,
ggplot2_3.2.0, tibble_2.1.3, tidyr_0.8.3, and dplyr_0.8.3 and their associated dependencies.

Gene expression perturbability
As a measure of gene expression perturbability we used the count of the number of conditions in
which a gene was differentially expressed relative to cell type DMSO controls. For most analyses
we used any change with a DESeq2 adjusted p-value less than 0.1, but also conducted analyses
with additional filters, such as minimum absolute values of log2FoldChange. We also considered
other measures of perturbability, as well, which are not included in the manuscript above, details
of which are available upon request.

Prioritization of highly perturbable genes for use in transdifferentiation and
reprogramming experiments
We chose to follow up on highly perturbable genes in transdifferentiation and reprogramming
experiments. In order to narrow down the list of transcription factors, we considered those 1) with
average expression of 50 TPM or greater in controls of the cell type of interest, 2) with at least 4
conditions in which they are up-regulated, and 3) that are up-regulated in more conditions than
they are down-regulated. Then we selected from these lists genes that were relatively unstudied
in the context of cardiac transdifferentiation and iPSC reprogramming, as far as we could find in
the literature.

Live cell Tra-1-60 imaging
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In a pilot reprogramming experiment without shRNA transduction, we conducted live-cell staining
of hiF-T-iPSC colonies Tra-1-60 with TRA-1-60 Alexa Fluor™ 488 Conjugate Kit for Live Cell
Imaging (Life Tech. A25618) according to the manufacturer’s instructions.

Alkaline phosphatase staining with colorimetry
We used the Vector Red Substrate kit (Vector Labs SK-5100) to stain hiF-T-iPSC colonies after
fixation on day 21 of reprogramming experiments. We fixed wells in 24-well format using 3.7%
formaldehyde for 3 minutes, and followed the manufacturer’s instructions.

Immunofluorescence
We performed immunofluorescence for several markers. For Tra-1-60 immunofluorescence of
hiF-T-iPSC samples that had already been stained with Vector Red, we blocked and
permeablized in 5% BSA + 0.1% Triton X-100 in PBS at room temperature for 30 min. Then we
washed samples in PBS and used Stemgent 09-0068 at 1:200 in 5% BSA + 0.1% Triton X-100
for 2 hours at room temp. We washed samples in PBS and stained with DAPI prior to imaging.
For cardiac Troponin immunofluorescence of iPSC-derived cardiomyocytes and
transdifferentiated samples, we fixed samples in 3.7% formaldehyde for 10 min at room temp,
washed in PBS, and permeablized with 70% Ethanol overnight at 4C. Independent of smFISH or
after the smFISH protocol, we performed immunofluorescence with Abcam ab45932 primary
(1:200) with goat anti-rabbit-Alexa 594 (1:200) secondary and Fisher MA5-12960 primary (1:200)
with donkey anti-mouse-Alexa 488 (1:200) secondary. We used samples in 3% BSA + 0.1%
Tween 20 for blocking/binding buffer. Primary antibody incubations of 1 hour and secondary
incubations of 30 min, both at room temperature. Samples were washed with PBS and stained
with DAPI prior to imaging.

Single-molecule RNA FISH
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We incubated our cells overnight at 37°C in hybridization buffer (10% dextran sulfate, 2× SSC,
10% formamide) with standard concentrations of RNA FISH probes (Table 2.2).(Padovan-Merhar
et al., 2015) The following morning, we performed two washes in wash buffer (2X SSC, 10%
formamide), each consisting of a 30-min incubation at 37°C. After the second wash, we rinsed
once with 2X SCC/DAPI and mounted the sample for imaging in and 2X SSC.(Raj et al., 2008)
We performed RNA FISH on cell culture samples grown on a Lab-Tek chambered coverglass
using 50 μL of hybridization solution spread into a thin layer with a coverslip and placed in a
parafilm-covered culture dish with a moistened Kimwipe to prevent excessive evaporation.
Imaging. We imaged each sample on a Nikon Ti-E inverted fluorescence microscope using a
60× Plan-Apo objective and a Hamamatsu ORCA Flash 4.0 camera. For 60× imaging of complete
cells, we acquired z-stacks (0.3 µm spacing between stacks). For 60× imaging of a large field of
cells with one plane each, we used Nikon Elements tiled image acquisition with perfect focus. All
image of stained cells were in different fluorescence channels using filter sets for DAPI, Cy3,
Alexa 594, and Atto 647N. The filter sets we used were 31000v2 (Chroma), 41028 (Chroma),
SP102v1 (Chroma),17 SP104v2 (Chroma) and SP105 (Chroma) for DAPI, Atto 488, Cy3, Atto
647N/Cy5 and Atto 700, respectively. A custom filter set was used for Alexa 594/CalFluor610
(Omega). We tuned the exposure times depending on the dyes used: 400 ms for probes in Cy3
and Alexa 594, 500 ms seconds for each probe in Atto 647N, and 50 ms for DAPI probes. We
also acquired images in the Atto 488 channel with a 400 ms exposure as a marker of
autofluorescence.
Image Processing
smFISH analysis of image scans and stacks was done as previously described using
rajlabimagetools changeset 775fd10
(https://bitbucket.org/arjunrajlaboratory/rajlabimagetools/wiki/Home) in MATLAB v2019a.(Shaffer
et al., 2017)
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